CONFIDENTIA L
The GlaxoSmithKline group of companies BEL116027
1Division :World wide Development
Information Type :Reporting and Anal ysis Plan (RAP)
Title :Reporting and Anal ysis Plan for BEL116027 A Phase IV, 
Open -label, Non- randomized, 52- Week Study  to Evaluate 
Treatment Holiday s and Rebound Phenomenon After 
Treatment with Belimumab 10 mg/kg in Sy stemic Lupus 
Erythematosus Subjects
Compound Number :GSK1550188
Effective Date :30-JAN-2019
Description:
The purpose of this RAP is to describe the planned anal yses and output to be 
included in the Clinical Study  Report for Protocol BEL116027.
This RAP is intended to describe the final anal yses required for the study . 
This RAP will be provided to the study  team members to convey  the content of the 
Statistical Analy sis Complete deliverable.
RAP Author(s):
Approver Date Approval Method
29-Jan-2019 emailDirector, Clinical Statistics
Copy right 2019 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2018N381035_00
PPD
CONFIDENTIA L
The GlaxoSmithKline group of companies BEL116027
2RAP Team Approval s:
Approver Date Approval Method
28-Jan-2019email
Manager, Immuno -Inflammation, Clinical 
Programming
28-Jan-2019email
Senior Director, Immuno -Inflammation, 
Clinical Development
28-Jan-2019email
Manager, Immuno-Inflammation, Clinical 
Data Management
18-Jan-2019email
Clinical Development Manager, Immuno -
Inflammation, PCPS
24-Jan-2019email
Medical Writing Director, I mmuno -
Inflammation, Clinical Development
22-Jan -2019email
Director, CPMS
24-Jan -2019email
SERM Director, II, GCSP 2018N381035_00
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CONFIDENTIA L
The GlaxoSmithKline group of companies BEL116027
3Clinical Statistics and Clinical Programming Line Approvals:
Approver Date Approval Method
Line Manager, Immuno -Inflammation, Clini cal 
Programming30-Jan-2019 Pharma TMF 
eSignature
Senior Director, Immuno -Inflammation, Clinical 
Statistics
On behalf of  (Line Manager, 
Immuno -Inflammation, Clinical Statistics)30-Jan-2019Pharma TMF 
eSignature
. 2018N381035_00
PPD
PPD
PPD
CONFIDENTIA L
BEL116027
4TABLE OF CONTENTS
PAGE
1.INTRODUCTION ...................................................................................................... 9
2.KEY PROTOCOL INFORMA TION ........................................................................... 9
2.1. Changes to the Protocol Defined Statistical Analysis Plan ............................ 9
2.2. Study Objective(s) and Endpoint(s) ............................................................. 11
2.3. Study Design .............................................................................................. 13
2.4. Statistical Hypotheses / Statistical Analyses ............................................... 14
3.PLANNED ANALYSES .......................................................................................... 15
3.1. Interim Analyses ......................................................................................... 15
3.2. Final Analyses ............................................................................................ 15
4.ANALYSIS POPULATIONS ................................................................................... 16
4.1. Protocol Deviations ..................................................................................... 16
5.CONSIDERATIONS FOR DATA ANALYSES AND DAT A HANDLING 
CONVENTIONS ..................................................................................................... 17
5.1. Study Treatment Descriptors ...................................................................... 17
5.2. Parent Studies ............................................................................................ 17
5.3. Baseline Definitions .................................................................................... 17
5.3.1. Baseline Definitions1.................................................................... 17
5.3.2. Derivations and Handling of Missing Baseline Data ..................... 19
5.4. Multicentre Studies ..................................................................................... 19
5.5. Other Considerations for Data Anal yses and Data Handling 
Conventions ................................................................................................ 20
6.STUDY POPULATION ANA LYSES ....................................................................... 21
6.1. Overview of Planned Demography, Baseline Characteristics and 
Medical History Analyses ............................................................................ 21
6.2. Baseline Disease Activity and Other Baseline Endpoints ............................ 21
6.3. Study Population Data for Maintenance Phase Subject Profile ................... 24
7.EFFICACY ANALYSES .......................................................................................... 25
7.1. Primary Efficacy Ana lyses .......................................................................... 25
7.1.1. Endpoint / Variables ..................................................................... 25
7.1.2. Summary Measure ...................................................................... 25
7.1.3. Population of Interest ................................................................... 25
7.1.4. Strategy for Intercurrent (Post -Random ization) Events ................ 25
7.1.5. Statistical Analyses / Methods ..................................................... 26
7.2. Secondary Efficacy Analyses ...................................................................... 26
7.2.1. Endpoint / Variables ..................................................................... 26
7.2.1.1. Rate of Flares ............................................................. 26
7.2.1.2. First Severe SFI Flare ................................................ 26
7.2.1.3. Rebound ..................................................................... 26
7.2.1.4. SELENA SLEDAI Scores ............................................ 26
7.2.2. Summary Measure ...................................................................... 27
7.2.2.1. Rate of Flares ............................................................. 27
7.2.2.2. First Severe SFI Flare ................................................ 27 2018N381035_00
CONFIDENTIA L
BEL116027
57.2.2.3. Rebound ..................................................................... 27
7.2.2.4. SELENA SLEDAI Scores ............................................ 27
7.2.2.5. Changes in C orticosteroid Use ................................... 27
7.2.3. Population of Interest ................................................................... 27
7.2.4. Strategy for Intercurrent (Post -Randomization) Events ................ 27
7.2.4.1. Rate of Flares and First Severe SFI Flare .................. 27
7.2.4.2. Rebound and SELENA SLEDAI Scores ..................... 28
7.2.4.3. Changes in Corticosteroid Use ................................... 28
7.2.4.3.1. Number of days of daily 
prednisone dose ≥7.5 mg/day 
and/or increased by 25 %........................ 28
7.2.4.3.2. Number of days of daily 
prednisone dose ≤7.5 mg/day 
and/or decreased by 25% ....................... 28
7.2.5. Statistical Analyses / Methods ..................................................... 28
7.3. Exploratory Efficacy Analyses ..................................................................... 29
7.3.1. Endpoint / Variables ..................................................................... 29
7.3.1.1. Physician Global Assessment (PGA) .......................... 29
7.3.1.2. SLICC/SDI .................................................................. 29
7.3.1.3. Renal Flare ................................................................ .29
7.3.2. Summary Measure ...................................................................... 29
7.3.2.1. Physician Global Assessment (PGA) and 
SLICC/SDI .................................................................. 29
7.3.2.2. Renal Flares ............................................................... 29
7.3.3. Population of Interest ................................................................... 29
7.3.4. Strategy for Intercurrent (Post -Randomization) Events ................ 29
7.3.4.1. Physician Global Assessment (PGA) .......................... 29
7.3.4.2. SLICC/SDI .................................................................. 30
7.3.4.3. Renal Flare ................................................................ .30
7.3.5. Statistical Analyses / Methods ..................................................... 30
7.4. Efficacy Data for Maintenance Phase Subject Profile ................................ .30
8.SAFETY ANALYSES ............................................................................................. 31
8.1. Adverse Events Analyses ........................................................................... 31
8.2. Adverse Events of Special Interest Analyses .............................................. 32
8.2.1. Endpoint / Variables ..................................................................... 32
8.2.1.1. Adverse Events of Special Interest ............................. 32
8.2.1.2. Post-infusion systemic reactions by infusion ............... 32
8.2.2. Summary Measure ...................................................................... 32
8.2.2.1. Adverse Events of Special Interest ............................. 32
8.2.2.2. Post-infusion systemic reactions by infusion ............... 33
8.2.3. Population of Interest ................................................................... 33
8.2.4. Strategy for Intercurrent (Post -Randomization) Events ................ 33
8.2.5. Statistical Analyses / Methods ..................................................... 33
8.3. Clinical Laboratory Analyses ....................................................................... 33
8.3.1. Endpoint / Variables ..................................................................... 34
8.3.1.1. Clinical Laboratory Results ......................................... 34
8.3.1.2. Clinical Laboratory Toxicity Grades ............................ 34
8.3.1.3. Clinical Laboratory Reference Range Shifts ............... 34
8.3.1.4. Immunoglobulin Results Relative to the Lower 
Limit of Normal ........................................................... 35
8.3.2. Summary Measure ...................................................................... 35 2018N381035_00
CONFIDENTIA L
BEL116027
68.3.2.1 .Clinical Laboratory Results ......................................... 35
8.3.2.2. Clinical Laboratory Toxicity Grades ............................ 35
8.3.2.3. Clinical Laboratory Reference Range Shifts ............... 35
8.3.2.4. Immunoglobulin Results Rela tive to the Lower 
Limit of Normal ........................................................... 35
8.3.3. Population of Interest ................................................................... 35
8.3.4. Strategy for Intercurrent (Post -Randomization) Events ................ 35
8.3.5. Statistical Analyses / Methods ..................................................... 35
8.4. Other Safety Analyses ................................................................................ 36
8.4.1. Endpoint / Variables ..................................................................... 36
8.4.1.1. Immunogenicity .......................................................... 36
8.4.1.2. Vital signs ................................................................... 37
8.4.2. Summary Measure ...................................................................... 37
8.4.2.1. Immunogenicity .......................................................... 37
8.4.2.2. Vital signs ................................................................... 37
8.4.3. Population of Interest ................................................................... 37
8.4.4. Strategy for Intercurrent (P ost-Randomization) Events ................ 37
8.4.4.1. Immunogenicity .......................................................... 37
8.4.4.2. Vital signs ................................................................... 38
8.4.5. Statistical Analyses / Methods ..................................................... 38
8.5. Safety Data for Maintenance Phase Subject Profile .................................... 38
9.PHARMACOKINETIC ANAL YSES ......................................................................... 39
9.1. Primary Pharmacokinetic Analyses ............................................................. 39
9.1.1. Endpoint / Variables ..................................................................... 39
9.1.2. Summary Measure ...................................................................... 39
9.1.3. Population of Interest ................................................................... 39
9.1.4. Strategy for Intercurrent (Post -Randomization) Events ................ 39
9.1.5. Statistical Analyses / Methods ..................................................... 39
10. POPULATION PHARMACOK INETIC (POPPK) ANALY SES.................................. 40
11.BIOMARKER ANALYSES ...................................................................................... 41
11.1. Primary Biomarker Analyses ....................................................................... 41
11.1.1. Endpoint / Variables ..................................................................... 41
11.1.2. Summary Measure ...................................................................... 41
11.1.2.1. B-Cells ........................................................................ 41
11.1.2.2. Autoantibodies, Immunoglobulins and 
Complement ............................................................... 41
11.1.2.3. BLyS Protein .............................................................. 41
11.1.3. Population of Interest ................................................................... 41
11.1.4. Strategy for Intercurrent (Post -Randomization) Events ................ 41
11.1.5. Statistical Analyses / Methods ..................................................... 41
11.2. Biomarker Data for M aintenance Phase Subjects ....................................... 42
12.REFERENCES ....................................................................................................... 43
13.APPENDICES ........................................................................................................ 44
13.1. Appendix 1: Protocol Deviation ................................................................... 44
13.2. Appendix 2: Schedule of Activities .............................................................. 45
13.2.1. Protocol Defined Schedule of Events ........................................... 45
13.2.2. Time and Events Table (Year 1) .................................................. 45 2018N381035_00
CONFIDENTIA L
BEL116027
713.2.3. Time and Events Table (Additional Years) ................................... 48
13.3. Appendix 3: Assessment W indows ............................................................. 50
13.3.1. Mapping of the Maintenance Phase Visits for Subjects 
with an Escape Visit ..................................................................... 50
13.3.2. Mapping of W eek 16 and 6 -month Follow -up Visits ..................... 50
13.3.3. Analysis Visit and Analysis Visit Number ..................................... 51
13.3.4. Windows for Assessment of Post -injection/infusion 
sensitivity reactions (PISR) and hypersensitivity reactions 
(HSR) .......................................................................................... 52
13.4. Appendix 4: Study Phases and Treatment Emergent Adverse 
Events ........................................................................................................ 53
13.4.1. Treatment Phases ....................................................................... 53
13.4.1.1. Treatment Holiday Group ........................................... 54
13.4.1.2. Treatment Control Group ............................................ 55
13.4.1.3. Long -term Discontinuation Group ............................... 56
13.5. Appendix 5: Data Display Standards & Handling Conventions .................... 58
13.5.1. Reporting Process ....................................................................... 58
13.5.2. Reporting Standards .................................................................... 58
13.5.3. Reporting Standards for Pharmacokinetic .................................... 59
13.6. Appendix 6: Derived and Transformed Data ............................................... 60
13.6.1. General ........................................................................................ 60
13.6.2. Study Population .......................................................................... 60
13.6.3. Efficacy ........................................................................................ 63
13.6.4. Safety .......................................................................................... 70
13.6.5. Pharmacokinetic .......................................................................... 71
13.6.6. Biomarker .................................................................................... 72
13.6.6.1. Autoantibody, Complement, Immunoglobulins, 
and BLyS Protein ....................................................... 72
13.6.6.2. B-cell Subsets ............................................................ 72
13.7. Appendix 7: Reporting Standards for Missing Data ..................................... 76
13.7.1. Prematur e Withdrawals ................................................................ 76
13.7.2. Handling of Missing Data ............................................................. 76
13.7.2.1. Handling of Missing and Partial Dates ........................ 77
13.7.3. Handling of Prohibited Medications, Withdrawals and 
Deaths ......................................................................................... 78
13.8. Appendix 8: Values of Potential Clinical Importance ................................... 79
13.8.1. Laboratory Values ........................................................................ 79
13.8.2. Adverse Event and Laboratory Value Severity Grade 
Tables .......................................................................................... 80
13.9. Appendix 9: Adverse Events of Special Interest .......................................... 89
13.9.1. Malignant neoplasms ................................................................... 89
13.9.2. Post-infusion systemic reactions .................................................. 90
13.9.3. Infections ..................................................................................... 92
13.9.3.1. Opportunistic Infections .............................................. 92
13.9.4. Mycobacterium Tuberculosis ....................................................... 92
13.9.5. Herpes Zoster .............................................................................. 92
13.9.6. Pneumonia .................................................................................. 92
13.9.7. Sepsis .......................................................................................... 92
13.9.8. Depression/suicide/self -injury ...................................................... 92
13.9.8.1. Depression (excluding suicide and self -injury) ............ 92
13.9.8.2. Suicide and Self -Injury ................................................ 93
13.9.9. Fatalities ...................................................................................... 93 2018N381035_00
CONFIDENTIA L
BEL116027
813.9.10. GSK SRT Adjudication of Adverse Events of Special 
Interest ........................................................................................ 93
13.9.10.1. Malignancies .............................................................. 93
13.9.10.2. Serious hypersensitivity and post -infusion 
systemic reactions ...................................................... 94
13.9.10.3. Potential opportunistic infections ................................ 94
13.9.10.4. Suicide/self -injury ....................................................... 96
13.9.10.5. Fatalities ..................................................................... 96
13.10. Appendix 10: Abbreviations & Trade Marks ................................................ 97
13.10.1. Abbreviations ............................................................................... 97
13.10.2. Trademarks ................................................................................. 98
13.11. Appendix 11: List of Data Displays .............................................................. 99
13.11.1. Data Display Numbering .............................................................. 99
13.11.2. Deliverables ................................................................................. 99
13.11.3. Study Population Tables ............................................................ 100
13.11.4. Study Population Figures ........................................................... 101
13.11.5. Efficacy Tables .......................................................................... 102
13.11.6. Efficacy Figures ......................................................................... 103
13.11.7. Safety Tables ............................................................................. 104
13.11.8. Safety Figures ........................................................................... 110
13.11.9. Pharmacokinetic Tables ............................................................. 111
13.11.10. Pharmacokinetic Figures ........................................................... 112
13.11.11. Biomarker Tables ....................................................................... 112
13.11.12. Biomarker Figures ..................................................................... 115
13.11.13. ICH Listings ............................................................................... 117
13.11.14. Non-ICH Listings ........................................................................ 120
13.12. Appendix 12: Example Mock Shells for Data Displays .............................. 121 2018N381035_00
CONFIDENTIA L
BEL116027
91. INTRODUCTION
The purpose of this reporting and anal ysis plan (RAP) is to describe the analy ses to be 
included in the Clinical Study  Report for Protocol 116027 :
Revision Chronology:
2012N154810_00 22-Aug-2013 Original
2012N154810_01 04-Oct-2013 Amendment 01
2012N154810_02 14-Jan-2014 Amendment 02 
2012N154810_03 01-Apr-2014 Amendment 03
2012 N154810_04 31-Aug-2015 Amendment 0 4
2012N154810_05 03-Dec-2015 Amendment 05
2012N154810_06 12-Sep-2017 Amendment 06
2. KEY PROTOCOL I NFORM ATION
A total of approximately  71subjects ( 10 in the treatment holiday  group, 26 in the 
treatment control group, and 35 in the long -term discontinuation group) will be enrolled 
in this study .  The total sample size is based on practical considerations on the availability  
of subjects from other ongoing belimumab studies, rather than on statistical 
considerations.  Since t his is a non- randomized study , results will be descriptive only , and 
not intended to be inferential.  No power calculations were made in the determination of 
sample size for this study.  However, the total of subjects is expected to provide adequate 
inform ation to characterize time to SL E flare.
Table 1 Flare Rates from Pooled BLISS Studies
ISE Table Analysis Placebo 1 mg/kg 10 mg/kg
T57 Percenta ge of Subjects 
with Flare Over 52 
Weeks81.5% 74.6% 74.6%
TAC411 Percentage of Subjects
with Flare Over 52 
Weeks Post Week 2468.5% 54.7% 57.5%
TAC613 Percentage of Subjects 
with Flare Over 52 
Weeks Among SRI Wk
52 Responders73.4% 69.8% 67.4%
2.1. Changes to the Protocol Defined Statistical A nalysis Plan
Changes from the originally  planned st atistical analy sis specified in the protocol are 
outlined in Table 2. 2018N381035_00
CONFIDENTIA L
BEL116027
10Table 2 Changes to Protocol Defined A nalysis Plan
Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statisti cal Analysis Plan Rationale for Changes
Partial prothrombin time (PTT) is 
collectedActivated partial 
prothrombin time (aPTT) 
time is analyzedaPTT was collected instead of 
PTT
Section 8.1.3 states that f or the 
primary analysis of the additional 
efficacy and biomarkers, the 
baseline will be defined as study 
Day 0 of the original parent 
study. Additionally, for some of 
theendpoints, a secondary 
analysis will be performed by 
defining the baseline as Day 0 of 
the BEL116027 study.The baseline for each 
endpoint is defined per 
Section 6.1 of the protocol.
.The protocol was inconsistent 
in the definition of baseline.
See RAP S ection 5.3 for 
clarification
Immunogenicity is listed as a 
secondary endpoint in Protocol 
Section 6.1.2., but as an 
exploratory laborat ory parameter 
in the Time and Events table.Immunogenicity is defined 
as a secondary endpoint.The protocol was inconsistent, 
so the correct category was 
used in the RAP.
Renal flares are not listed as an 
endpoint in Protocol Section 
6.1.2 nor described i n Protocol 
Section 8, but are defined in 
Protocol Section 6.1.4Renal flares are included as 
an exploratory endpoint in 
RAP Section 2.2.The protocol was inconsistent, 
so the endpoint was correctly 
specified in the RAP.
The definition of renal flare 
contained a typographical error 
and referenced an increase 
rather than a decrease in GFR.  
This was corrected in a note to 
file.The RAP specifies the 
correct definition, 
referencing a decrease in 
GFR.The protocol was incorrect.
Protocol Section 6.1.3 lists 
percent change in PGA .The RAP specifies change 
from baseline in PGA 
instead.Change from baseline is more 
clinically relevant and 
interpretable, particularly in 
the case of low baseline 
scores.
Protocol Section 6.1.2 lists one 
time interval for percent ch ange 
in B-cell subsets from Week 24, 
i.e., Week 24 to 52. In addition to this, the RAP 
specifies percent change 
from Week 24 to 32 and 
Week 24 to 40.The additional time intervals 
facilitate interpretation of the 
changes follow ing the 
treatment holiday ph ase.
The protocol Section 6.1.2 does 
not list the CD19+ B -cell subset.The RAP adds the CD19+ 
B-cell subset.This subset is collected and 
clinically important.
The protocol Section 6.1.3 Other 
Endpoints includes percent 
change in prednisone dose and 
percent of subjects with 
prednisone dose reduced to 
<7.5mg/day from ≥7.5mg/day. .These two exploratory 
endpoints were not 
analysedThe two secondary 
prednisone endpoints
(Protocol S ection 6.1.2 )will 
be analysed as they are most 
descriptive in that they asses s 
daily prednisone use. Given 
the reduced sample size from  2018N381035_00
CONFIDENTIA L
BEL116027
11Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statisti cal Analysis Plan Rationale for Changes
the original protocol, these two 
endpoints allow sufficient 
evaluation of the impact of the 
treatment holiday.
Section 6.1.2 lists percent 
change from baseline in B -Cells, 
immunoglobulins and aut o-
antibodies Change from baseline will 
also be presented for these 
parameters.Change from baseline added 
based on regulatory feedback 
on other studies in the 
belimumab development 
program.
2.2. Stud y Objective(s) and Endpoint(s)
Objectives Endpoints
Primar y Objectives Primary Endpoints
Characterize the efficacy of a 
24-week withdrawal followed by 
a 28-week reintroduction of 
intravenous belimumab therapy 
compared with uninterrupted 
intravenous belimumab therapy 
for 52 weeks in subjects with low 
SLE disease activity receiving 
belimumab 10 mg/kg plus 
standard of care, as measured 
by time to first flare.Time to any SLE Flare Index flare.
Secondary Objectives Secondary Endpoints
 Evaluate the rate of any flare. Rate of any SLE Flare Index flare per subject year.
Time to first SLE Flare Index severe flare.
Assess safety. Adverse events
AESI
Laboratory parameters
Vital signs
Assess SLE disease activity. Number of subjects in the treatment holiday and long -term 
discontinuation group with evidence of rebound (def ined as 
a SELENA SLEDAI score during the first 24 weeks that 
exceeds the baseline SELENA SLEDAI score in the 
subjects’ respective original parent study ).
SELENA SLEDAI scores change from baseline.
Assess immunogenicity. Response (Negative, Transient Positive, Persistent Positive) 
by Visit and Across All Visits
Assess markers of autoimmune 
response (e.g., 
immunoglobulins, complement.)Change and Percent change from baseline in IgG, IgM, IgA, 
anti-dsDNA, ANA, C3, and C4.
Shifts from baseline in IgG, IgM, I gA, anti -dsDNA, ANA, C3 
and C4.
Change and Percent change in absolute B cell subsets  2018N381035_00
CONFIDENTIA L
BEL116027
12Objectives Endpoints
(CD19+, CD20+, CD20+/27+ memory, CD20+/27 –naïve, 
CD20+/69+ activated, CD20+/138+ plasmacytoid, 
CD19+/27BRIGHT/38BRIGHT SLE subset and CD20 -/138+ 
plasma cells) at Weeks 0, 8, 16, 24, 32, 40 and 52 and from 
Weeks 24 to 52.
Assess changes in 
corticosteroid use. Number of days of daily prednisone dose 7.5 mg/day 
and/or increased by 25% from Day 0 of this study to Week 
24, from Day 0 of this study to Week 52, and from Week 24
to Week 52.
 Number of days of daily prednisone dose 7.5 mg/day 
and/or decreased by 25% from Day 0 of this study to Week 
24, from Day 0 of this study to Week 52, and from Week 24 
to Week 52.
Exploratory/ Other Exploratory/ Other Endpoints
Time to first r enal flare
Time to first renal flare among subjects with baseline 
proteinuria >0.5g/24hr equivalent
Change from Baseline in PGA
Change and percentage change from Baseline in BLyS 
Protein
SLICC/SDI
Change from Baseline 2018N381035_00
CONFIDENTIA L
BEL116027
132.3. Stud y Design
Overview of Study Desig n and Key Features
Design Features A phase IIIB, multi -centeropen -label, non- randomized study.
Dosing  Treatment Holiday (TH) group : Temporary discontinuation 
(24 weeks) and re -introduction of belimumab 10 mg/kg 
therapy. The target enrolment for this group is 10subjects.
 Treatment Control (TC) group: Continued treatment with 
belimumab 10 mg/kg. The target enrolment for this group is 
26subjects.
Long- term Discontinuation (LTD) group : Discontinued 
therapy with belimumab 10 mg/kg and are expected to rem ain 
off be limumab therapy for at least 12 months but remain on 
standard of care therapy. The target enrolment for this group is 
35subjects.
Time & Events Refer to Appendix 2 : Schedule of Activities
Treatment Assignment  Non-randomiz ed, open label
Interim Analysis The protocol indicated that a n interim anal ysis of the 
data in this trial may  be performed to support a 
submission to regulatory  authorities relating to 
marketing authorization (e.g., to summarize and submit  2018N381035_00
CONFIDENTIA L
BEL116027
14Overview of Study Desig n and Key Features
this lo ng-term safet y data to regulatory authorities in the 
initial BL A and other marketing authorization 
submissions). Additional interim analyses may  be 
required to support subsequent safet y updates to 
regulatory  authorities. No interim analyses were conducted .
Sampl e Size  The total target sample size was71 subjects and 80 were 
enrolled .  The target sample size for subjects in the treatment 
holiday and control groups was 10(12 enrolled) and 26 (29 
enrolled) subjects respectively.  A target sample size of 35 (39 
enrolled) subjects in the long -term discontinuation group was
anticipated. .
Note:  Subjects from China participated in BEL113750 OL phase rather than in BEL114333,and were therefore eligible 
to enter BEL116027 from BEL113750 OL, per a China country -specific protocol amendment 01.
2.4. Statistical Hy potheses /Statistical Analyses
Since this is a non- randomized study , results will be descriptive onl y, and any 
comparisons are not intended to be inferential .  2018N381035_00
CONFIDENTIA L
BEL116027
153. PLANNED ANAL YSES
3.1. Interim Analyses
The protocol indicated that a n interim anal ysis of the data in this trial may  be performed 
to support a submission to regulatory  authorities relating to marketing authorization (e.g., 
to summarize and submit this long -term safet y data to regulatory authorities in the initial 
BLA and other marketing authorization submissions). Additional interim anal yses may  
be required to support subsequent safet y updates to regulatory  authorities. No interim 
analyses were conducted. 
The SRT performs in stream adjudication of subject- level saf ety data for Adverse Events 
of Special Interest (AESIs; serious and non -serious) in accordance with the GSK 
Standard Operating Procedures (SOPs) and the belimumab Program Safety Analy sis Plan 
(PSAP).AESI s include malignancy ; serious hy persensitivity  and post-infusion systemic 
reactions; potential opportunistic infections; other infections of interest but not generall y 
considered opportunistic i.e. Mycobacterium Tuberculosis and Herpes Zoster; 
suicide/self -injury ; and fatalities .
AESI s are flagged in the clinical trial database, according to SRT adjudication.  The SRT 
performs a periodic review of instream stud y data (at least every 6 months), reviewing 
the c umulative incidence of AEs, SAEs, and adjudicated AESIs.  These periodic reviews 
of cumulative adve rse event incidence are compared with previous SRT reviews and 
where appropriate, the pivotal SL E pooled data to assess for an y new safet y signals.
3.2. Final A nalyses
The final planned primary  analy ses will be performed after the database cleaning 
activities have been completed and final database release and database freeze has been 
declared b y Data Management :
database cleaning activities have been completed and final database release and database 
freeze has been declared by  Data Management.
In this open -label , non -randomized study , for dispensing of stud y drug, r andomisation 
codes have been distributed according to RandAll NG procedures. 2018N381035_00
CONFIDENTIA L
BEL116027
164. ANALYSIS P OPUL ATIONS
Population Definition / Criteria Analyses Evaluated
Screened Comprise sall subjects who enroll in the study, 
including screen failuresStudy population
Intent -To-Treat Comprise sall subjects who enroll in the study , 
excluding screen failures .Study population
Efficacy
Safety
Biomarker
PK Comprise sall subjects included in the ITT 
population for whom at least one post 
belimumab treatment PK sample was obtained 
and analyzed.  PK
1. NOTES: 
 Please refer to Appendix 11: List of Data Displays which details the population to be used for each display being 
generated.
4.1. Protocol Deviations
Important protocol deviations (including deviations related to study  inclusion/exclusion 
criteria, conduct of the trial, patient management or patient assessment) will be identified 
in the Protocol Deviation Management Plan (PDMP).
Protocol deviations will be tracked b y the stud y team throughout the conduct of the study 
in accordance with the PDMP.
Data will be reviewed prior to freezing the database to ensure all important 
deviations are captured and categorised on the protocol deviations dataset. 
This da taset will be the basis for the summaries and listings of protocol 
deviations.
Important protocol deviations (including deviations related to study  inclusion/exclusion 
criteria, conduct of the trial, patient management or patient assessment) will be 
summar ised and listed. 2018N381035_00
CONFIDENTIA L
BEL116027
175. CONSIDERA TIONS FOR D ATA ANALYSES AND DATA
HANDLING CONVENTIONS
5.1. Stud y Treatment Descriptors
Treatment Group Descriptions
RandAll NG Data Displays for Reporting 
Group 
CodeGroup Description Description Order [1]
3 Long Term Discontinua tion Group Long -term Discontinuation 1
2 Control Group Treatment Control 2
1 Treatment Holiday Group Treatment Holiday 3
NOTES:
1. Order represents treatments being presented in TFL, as appropriate.   Some Tables will only present TC and TH 
groups.
2. In appli cable data listings, Screen Failures will be presented first followed by LTD, TC and TH.
5.2. Parent Studies
Subjects were eligible to enter BEL116027 from one of four continuation studies, having 
entered the continuation study  from a respective parent study . The possible study  
participation sequences are as follows:
Parent Study Continuation Study Subjects
BEL113750 DB1BEL113750 OL1 Subjects from China
BEL1123412 BEL114333 Some subjects from Japan
BEL113750 BEL114333 Subjects from Korea and some subject s from Japan
BEL110751 BEL112233 (C1066) Subjects from US
LBSL02 LBSL99 (BEL112626) Subjects from US
1. BEL113750 was both the parent and continuation study number for subjects enrolled in China.
2. Subjects from Japan who participated in study BEL112341 were eligible to enrol into the BEL114333 
continuation phase per a BEL114333 protocol amendment, to allow them continued access to study agent 
until belimumab was commercially available in Japan.
5.3. Baseline Definition s
5.3.1. Baseline Definitions1
The baseline (BL) definition is dependent upon the endpoint being anal yzed.
For the SELENA SLEDAI (including rebound), immunoglobulins, auto -
antibodies, complement, BLyS and B -cell endpoints, baseline is defined as the 
Day 0 assessment in the subject’s respective parent stud y, prior to exposure with 
study  treatment (whether placebo or belimumab). Baseline data for these  2018N381035_00
CONFIDENTIA L
BEL116027
18parameters will be extracted from the ADaM data sets from the double blind 
study (LBS L02, BEL110751 ,BEL113750 or BEL112341 )from which the 
patients are enrolled .
For the SLE flares, SLE severe flares, SLICC, prednisone (7 day  average prior 
to Day 0), PGA, and immunogenicit y2, endpoints, baseline is the Day  0 
assessment in BEL116027.
For other endpoints, baseline is the Day  0 assessment in BEL1160272.
1Feeder study  BEL114333 database had not y et completed at the time of BEL 116027 
Last Patient Last Visit. Consequently , baseline data for BEL114333 patients has not 
been full y cleaned when extracted fr om that stud y’s database for reporting .
2Assessments covered fo r both D ay 0in BEL116027 and the Exit/Follow -upvisit of 
the feeder continuation studies were only to be performed once and were to be 
recorded in the appropriate case report forms for each study . For Day  0 values not 
recorded in BEL116027 CRF but exist in the feeder study , the data will be extracted 
from the appropriate feeder study  for inclusion in anal ysis
In the display s, the baseline value/visit will be denoted as Baseline.
See Section 13.4.1 for a diagram depicting the ba seline definitions and phases. 2018N381035_00
CONFIDENTIA L
BEL116027
195.3.2. Derivations and Handling of Missing Baseline Data
Definition Reporting Details
Change from Baseline =Post- Dose Visit Value – Baseline
% Change from Baseline = 100 x [(Post -Dose Visit Value –Baseline) / Baseline]
Maximum Change from Baseline = Calculate the change from baseline at each given timepoint 
and determine the maximum change
NOTES:
 Unless otherwise specified, the baseline definitions specified in Section 5.3.1 Baseline Definitions will be used for 
derivations for endpoints / parameters and indicated on summaries and listings.
 Unless otherwise stated, if baseline data is missing no derivation will be performed and baseline will be set to 
missing.
5.4. Multicentre Studies
In this multicentre global study , enrolment will be presented b y investigative site, and in 
selected display s by country  and investigative site .
Since this is a non- randomized study , results will be descriptive onl y, and there will be no 
methods applied to ad dress multiple centers. 2018N381035_00
CONFIDENTIA L
BEL116027
205.5. Other Considerations for Data A nalyses and Data Handling 
Conventions
Other considerations for data anal yses and data handling conventions are outlined in the 
appendices:
Section Component
13.1 Appendix 1 : Protocol Deviation Management and Definitions for Per Protocol 
Population
13.2 Appendix 2 : Schedule of Activities
13.3 Appendix 3 : Assessment Windows
13.4 Appendix 4 : Study Phases and Treatment Emergent Adverse Events
13.5 Appendix 5 : Data Display Standards & Handling Conventions
13.6 Appendix 6: Derived and Transformed Data
13.7 Appendix 7 : Reporting Standards for Missing Data
13.8 Appendix 8 : Values of Potential Clinical Importance
13.9 Appendix 9 :  Adverse Events of Special Interest
13.11 Appendix 10: Abbr eviations & Trade Marks
13.12 Appendix 11: List of Data Displays
13.12 Appendix 12: Example Mock Shells for Data Displays 2018N381035_00
CONFIDENTIA L
BEL116027
216. STUDY POPULA TION ANALYSES
6.1. Overview  of Planned Demography , Baseline Characteristics
andMedical History A nalyses
The study  population analy ses including analy ses of subject’s disposition, protocol 
deviations, demographic and baseline characteristics, medical conditions, prior and 
concomitant medications, and exposure and treatment compliance will be based on the 
ITT population, or for the Screened population where specified.  Data will be presented 
by treatment group and for all subjects combine d, unless otherwise specified.
Fulldetails of data displays being presented in Appendix 11: List of Data Display s.
Completion and withdrawal status by  treatment phase is defined in Section 13.6.2 .
6.2. Baseline Disease Activity  and Other Baseline E ndpoints
A summary  of baseline disease activity  will be provided, including counts and 
percentages for categorical endpoints and d escriptive statistics for the continuous 
endpoints and scores.
Table 3 provides indi cators of baseline disease activity  that will be summarized.  Some of 
these parameters will be summarized on the by  visit summary  for that parameter 
according to the table specifications. 2018N381035_00
CONFIDENTIA L
BEL116027
22Table 3 Baseline Disease A ctivity  Endpoints
Endpoint Categories & Summaries at Baseline
SELENA -SLEDAI category Continuous
Categorical
0, 1, 2, 3
SELENA SLEDAI by organ domain 
and item at baselineCategorical
Presented if Yes
Complement & BLyS Levels Complement C3 and C4 (mg/dL)
Continuous
Catego rical
Positive, Negative
Low, Normal, High
(See Section 13.6.6 for definitions)
BLyS Protein [ng/mL]
Continuous
Categorical
Below LLOQ: <0.061 ng/mL for China samples and 
<0.02048 ng/mL for all others
SLE Flare Index Categori cal
At least 1 flare, At least 1 severe flare  
PGA  Continuous
Categorical
0-1, >1 – 2.5, > 2.5
SLICC/ACR Damage Index Continuous
Categorical
0, 1, > 1 2018N381035_00
CONFIDENTIA L
BEL116027
23Endpoint Categories & Summaries at Baseline
Proteinuria (based on spot urine using 
protein: creatinine mg/mg ratio)Continuous
Categorical (units are g/24hr equivalent)
≤ 0.5 , > 0.5
Subcategories of > 0.5 
>0.5 - < 1
1 -< 2
≥ 2
B cells: 
CD19+
CD20+
CD20+/27+ memory
CD20+/27 – naïve
CD20+/69+ activated
CD20+/138+ plasmacytoid
CD19+/27BRIGHT /38BRIGHT SLE subset
CD20 -/138+ plasmaContinuous
Autoantibody Levels Anti-dsDNA [IU/mL]
Continuous
Categorical
Positive : >=30 IU/mL
Negative: <30 IU/mL
ANA [Titer]
Continuous
Categorical
Positive: Index >=0.80
Negative: Index <0.80
aCL Status
Categorical
Positive, Negative , Missing (See Section 13.6.6 for 
definitions)
anti-dsDNA and/or ANA positive Categorical
Yes, No
Immunoglobulin Levels (IgG, IgA, and 
IgM [g/L])Continuous
Categorical
IgG
Low:  < 6.94 g/L, High:  > 16.18 g/L
IgM
Low: < 0.48 g/L, High:  > 2.71 g/L  
IgA
Low:  < 0.81 g/L, High:  > 4.63 g/L 2018N381035_00
CONFIDENTIA L
BEL116027
24Endpoint Categories & Summaries at Baseline
Allowable SLE Medication Usage Categorical:
Steroid Only
Immunosuppressant Only
Anti-malarial Only
Steroid and Immunosuppressant Only
Steroid and Anti -Malarial Only
Immunosuppressant and Anti- Malarial Only
Steroid and Immunosuppressant and Anti- malarial
Traditional Chinese Medicine -Glycosides of 
Paeony/Tripterygium
Average daily prednisone dose 
(mg/day) at baselineContinuous
Categorical
0, >0 to ≤7.5, >7.5
PT/aPTT Continuous
6.3. Stud y Population Data for Maintenance Phase Subject 
Profile
Basic demograph y information will be listed on the subject profile. 2018N381035_00
CONFIDENTIA L
BEL116027
257. EFFICA CY ANALYSES
For all efficacy  analy ses, results for the TH group will be presented for the treatment 
holiday  (TH) and re -start (RS) phases separatel y.
7.1. Primary  Efficacy  Analy ses
7.1.1. Endpoint / Variables
The time to the first SFI flare over 52 weeks will be estimated for the treatment groups 
using the product -limit method. 
Analy ses of SFI flare (defined as mild, moderate, or severe) will be performed on the 
SELENA SLEDAI SLE flare index. Note: Flares in this study  are anal ysed using the 
modified SL E flare index where severe flares that are triggered onl y by an increase in 
SELENA SLEDAI score to gr eater than 12 are not categorized as severe in the anal ysis.
7.1.2. Summary  Measure
Only  post -baseline flares will be considered in these anal yses.  Flares (not subjects) 
occurring on the Day  0 visit date should be removed from the anal ysis set prior to 
determini ng the first flare.
Data observed at or prior to the baseline visit (see Section 5.3.1 ) will not be included in 
this analy sis.  
Time to fi rst SFI flare is defined as the number of day s from baseline date (see S ection 
5.3.1 )to the date the subject has a flare (event date – baseline visit date + 1). 
See Section. 13.6.3 for additional details .
7.1.3. Population of Interest 
The primary  efficacy  analy ses will be b ased on ITTpopulat ion.
7.1.4. Strategy  for Intercurrent (Post -Randomization) Events
The disposition of subjects as it relates to intercurrent events is defined as follows :
Subject DispositionEvent 
Met Event Date [2]
Subject has a SFI flare or takes a prohibite d medication
Subject has a SFI flare during the study 
[1]Yes Date of first SFI flare
Subject takes a prohibited medication [1] Yes Date of prohibited medication
Subject does not have a SFI flare and did not take a prohibited medication.
Subject withdr aws from the study or is 
lost to follow -upNo Censored at last available date where 
flare is assessed.
Subject dies during the study No Censored at date of death. 2018N381035_00
CONFIDENTIA L
BEL116027
26Subject completes the study No Censored at last study visit where flare is 
assessed.
[1] If a subject has a SFI flare and takes a prohibited medication, the event date is the earliest of 
the first SFI flare date and takes a prohibited medication date.
[2] If a subject meets multiple criteria, then the event date is the earliest date.
7.1.5. Statisti cal A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 7.1.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and
listed.
The table will display  the number and percentage of subjects with a SFI flare, as well as 
the median, 25th, and 75th percentile of day s to first SFI  flare, estimated using the 
product -limit method.  For subjects who experience a SFI flare, the study  day of the SFI 
flare will be summarized and the table will display the median, 25th and 75th percentiles 
and minim um and maximum.
A cumulative incidence curve for time to first SFI flare will also be produced for the 52 -
week treatment phase.
7.2. Secondary  Efficacy A nalyses
7.2.1. Endpoint / Variables
7.2.1.1. Rate of Flares
The unadjusted rate of flares per subject -year over 52 w eeks wil l be summarized by  
treatment group.
7.2.1.2. First Severe SFI Flare
The time to the first severe SFI flare over 52 weeks will be estimated for the treatment 
groups using the product -limit method.
7.2.1.3. Rebound
Rebound is defined as a SEL ENA SLEDAI score during the first 24 weeks that exceeds 
the baseline SELENA SLEDAI score in the subject’s respective original parent study .
7.2.1.4. SELENA  SLEDA I Scores
SELENA SLEDAI assessments consist of 24 individual weighted items in which signs 
and sy mptoms, laboratory  tests, and phy sician’s assessment for each of 8 organ s ystems 
are given a weighted score and summed if present (marked ‘Yes’) at the time of the visit 
or in the preceding 10 day s. The maximum theoretical score is 105 (all 24 descriptors  2018N381035_00
CONFIDENTIA L
BEL116027
27present simultaneously ) with 0 indicating inactive disease (marked ‘No’), but in practice 
few subjects have scores > 45 [ Buyon, 2005 ; Petri , 2005 ]. 
See Section 13.6.3 for further details.
7.2.2. Summary  Measure
7.2.2.1. Rate of Flares
The total number of flares, total subject -years of follow -up in the time interval, and the 
unadjusted rate per subject- yearwill be presented.
7.2.2.2. First Severe SFI Flare
See Section 7.1.2 .
7.2.2.3. Rebound
The frequencies and percentages of subjects who rebound will be presented by visit 
through the Week 24 visit, and at any time during the first 24 weeks.
7.2.2.4. SELENA  SLEDA I Scores
Summary  statistics for the change from baseline in SEL ENA SLEDAI scores will be 
present ed at each visit in the 52 -week treatment phase.
7.2.2.5. Changes in Corticosteroid Use
The frequencies and percentages of subjects who meet each definition will be presented 
at each visit in the 52 -week treatment phase .Steroid doses will be converted to the 
predn isone -equivalent dose per the derivations in Section. 13.6.3
7.2.3. Population of Interest 
The secondary efficacy  analy ses for all endpoints will be based on the ITTpopulation .
For rebound, the analy sis also will be performed by  the SELENA SL EDAI score at the 
BEL116027 Day  0 visit, categorized as ≤3 and >3. 
7.2.4. Strategy  for Intercurrent (Post -Randomization) Events
7.2.4.1. Rate of Flares and First Severe SFI Flare
See Section 7.1.4 . 
If a subject withdraws from the study , dies or takes a prohibited medication, the subject 
will be considered as having a SFI flare. 2018N381035_00
CONFIDENTIA L
BEL116027
287.2.4.2. Rebound and SELENA  SLEDA I Scores
Missing data will be imputed using the principle of Last Observation Carried Forward 
(LOCF ).  For the TH group, L OCF will not be applied across the TH and RS phases.  If 
an individual SS item data is missing at the first timepoint in the RS phase, the item will 
be considered not present.  
7.2.4.3. Changes in Corticosteroid Use
7.2.4.3.1. Number of day s of daily  prednison e dose ≥7.5 mg/day and/or increased 
by 25% 
The Dropout (DO)/Prohibited Medication (PM)=Non -responder (NR) imputation will be 
applied.  If a subject withdraws from the stud y and/or receives a protocol- prohibited 
medication, the subject will be considered t o have met this endpoint criteria (i.e, dose ≥ 
7.5 mg/day  and/or increased by  25%) after the date of dropout or the date that the 
medication is started, whichever comes first, up until the visit date, and for those day s in 
intervals for subsequent attended visits. Before this date, the evaluated endpoint will be 
assessed using available data .  
7.2.4.3.2. Number of day s of daily  prednisone dose ≤7.5 mg/day and/or 
decreased by  25%
The Dropout (DO)/Prohibited Medication (PM)=Non -responder (NR) imputation will be 
applied .  If a subject withdraws from the stud y and/or receives a protocol- prohibited 
medication, the subject will be considered a non -responder for this endpoint criteria (i.e., 
dose >7.5 mg/day  and/or did not decreased b y 25% ) after the date of dropout or the d ate 
that the medication is started, whichever comes first, and for those day s in intervals for 
subsequent attended visits. Before this date, the evaluated endpoint will be assessed using 
available data.
7.2.5. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 7.2.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed. 2018N381035_00
CONFIDENTIA L
BEL116027
297.3. Exploratory  Efficacy  Analyses
7.3.1. Endpoint / Variables
7.3.1.1. Physician Global A ssessment (PGA )
The change from baseline in PGA score will be assessed at each visit in the 52 -week 
treatment phase.   See Section. 13.6.3 for additional details on the instrument.
7.3.1.2. SLICC/SDI
The change from baseline in SLICC/SDI score will be assessed at each visit in the 52 -
week treatment phase.
7.3.1.3. Renal Flare
The time to the first renal flare over 52 weeks will be estimated for the treatment groups 
using the product -limit method. See Section 13.6.3 for additional details .
7.3.2. Summary  Measure
7.3.2.1. Physician Global A ssessment (PGA )and SLICC/SDI
These endpoints will be analy zed using summary statistics .
7.3.2.2. Renal Flares
Only  post -baseline renal flares will be considered in these anal yses.  Renal flares (not 
subjects) occurring on the Day  0 visit date should be removed from the analy sis set prior 
to determining the first renal flare.
Data observed at or prior to the baseline visit (see Section 5.3.1 ) will not be included in 
this analy sis.  
Time to fi rst renal flare is defined as the number of day s from base line date (see Section 
5.3.1 )to the date the subject has a renal flare (event date – baseline visit date + 1).
7.3.3. Population of Interest 
The anal yses for all exploratory  endpoints will be based on the ITTpopulation .
For renal f lares, the analy sis will be repeated for subjects with baseline proteinuria 
proteinuri a >0.5g/24hr equivalent.
7.3.4. Strategy  for Intercurrent (Post -Randomization) Events
7.3.4.1. Physician Global A ssessment (PGA )
Missing data will be imputed using LOCF.   For the TH grou p, LOCF will not be applied 
across the TH and RS phases. 2018N381035_00
CONFIDENTIA L
BEL116027
307.3.4.2. SLICC/SDI
Missing data due to study  withdrawal will be imputed using LOCF . For the TH group, 
LOCF will not be applied across the TH and RS phases.
The SLICC/ACR Damage Index increases over time. Once a subject meets the criteria for 
positive scoring of an item, that item should alway s be marked as present, even if the 
subject subsequently  recovered.  
In the event the SLICC/ACR Damage Index is scored inconsistently  (a decrease relative 
to previous ite ms has occurred) and the data are unable to be queried and/or corrected, a 
worst observation carried forward (WOCF) approach will be used at th e item level for the 
SLICC/ACR Damage Index questions.  These WOCF values will then be used to 
calculate the tota l score which will be the value summarized and displayed for reporting.
7.3.4.3. Renal Flare
The disposition of subjects as it relates to intercurrent events is defined as follows :
Subject Disposition Event Met Event Date [2]
Subject has a renal flare or takes a p rohibited medication
Subject has a renal flare [1] Yes Date of first renal flare
Subject takes a prohibited 
medication [1]Yes Date of prohibited medication
Subject does not have a renal flare and did not take a prohibited medication
Subject withdraws No Censored at last flare 
assessment date
Subject dies No Censored at date of death
Subject completes No Censored at the Week 52 
study visit
[1] If a subject has a renal flare and takes a prohibited medication, the event date is the earliest of 
the fir st renal flare date and takes a prohibited medication date.
[2] If a subject meets multiple criteria, then the event date is the earliest date.
7.3.5. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 7.3.1 will be 
summarised using descriptive statistics, graphicall y presented (where appropriate) and 
listed.
7.4. Efficacy  Data for Maintenance Phase Subject Profile
Flare data will be listed on the subject profile. 2018N381035_00
CONFIDENTIA L
BEL116027
318. SAFETY ANAL YSES
The safet y analyses will be based on the ITTpopulation, unless otherwise specified.
8.1. Adverse E vents Analyses
Adverse events analy sesincluding the anal ysis of adverse events (AEs), serious adverse 
events (SAEs) , and other significant AEs will be based on GSK Core Data Standards. 
The details of the planned display s are provided inAppendix 11: List of Data Display s.
Adverse events will be coded to the current MedDRA dictionary  version available at the 
time of reporting.
Only  treatment emergent AEs will be summarized (see Section 13.4.1 ).  Any AEs that 
were ongoing in the upon entry  into this will be listed and flagged with a footnote   
An overall summary  of AEs will be presented showing the number (%) of subjects with 
at least one of the following: AE, related AE, SAE, severe AE, SAE and/or severe AE , 
AE resulting in study  treatment discontinuation, and deaths. 
The number of events and the number (%) of subjects experiencing an AE by SOC, SOC 
and PT, and PT will be summarized for each of the AE categories below.
All
Serious
Severe
Study  agent Relate d
Resulting in discontinuation of study  treatment
The data will be sorted by overall decreasing frequency  of the SOC, by  overall 
decreasing frequency  of the SOC and then decreasing frequency  of PT within the SOC, 
and by  overall decreasing frequency  of the PT, as applicable .Only SOCs with observed 
AE PTs will be presented. If the frequency for any two or more adverse events is equal, 
the events will be presented in alphabetical order by SOC/PT as applicable.
Summaries of AEs frequency by SOC and severity  will also be provided.  For these 
display s, the number and percentage of subjects will be summarized as mild, moderate, or 
severe based on the maximum severity  observed across all PTs within the SOC for a 
given subject.
The hierarchical relationship betwee n MedDRA SOCs, PTs, and verbatim text will be 
display ed in a table for all AEs.
A listing of which subjects reported each AE will be produced.  AEs will be grouped and 
sorted by  SOC and PT. A listing of Infusion Related Sy stemic Reactions will be 
produced . 2018N381035_00
CONFIDENTIA L
BEL116027
328.2. Adverse Events of Special Interest Analyses
8.2.1. Endpoint / Variables
8.2.1.1. Adverse Events of Special Interest
A comprehensive list of MedDRA terms based on clinical review will be used to identify 
each t ype of event. Changes to the MedDRA dictionary  may  occur betw eenthe start of 
the study  and the time of reporting and/or emerging data from on- going studies may  
highlight additional adverse events of special interest, therefore the list of terms to be 
used for each event of interest and the specific events of intere st will be based on the 
safet y review team (SRT) agreements in place at the time of reporting. The details of the 
planned display s are provided in Appendix 11: List of Data Display s.
Adverse events of special interest for belimumab h ave been identified over the course of 
the development program. The Benl ysta Program Safety  Anal ysis Plan (PSAP) includes 
the definitions and adjudication criteria for the AESI .  The definitions are based on 
standard and custom MedDRA queries (SMQs and CMQ s).  Categorizations for the 
AESI  are listed in Section 13.9.
GSK will adjudicate neoplasms of unspecified malignancy , opportunistic infections, 
herpes zoster, serious suicide, and serious PI SR events as described in the PSAP. In 
addition, GSK will review malignancy  events to prevent counting an event multiple times 
in the case where a given malignancy  has multiple events (e.g., a diagnostic test and the 
diagnosis).  GSK will review all fatal events and assign a category of dea th.
8.2.1.2. Post -infusion sy stemic reactions by  infusion
For the TH group in the RS phase, summaries of post -infusion sy stemic reactions will be 
presented by the first six infusions in the RS phase and PT for the following categories :
Post-Infusion S ystemic Reacti ons per Anaph ylactic Reaction CMQ broad search (on 
the day  of the infusion or within 3 days after the infusion)
Serious Post -Infusion S ystemic Reactions per Anaphylactic Reaction CMQ broad 
search (on the day  of the infusion or within 3 day s after the infusion)
Serious Acute Post -Infusion Sy stemic Reactions/Hy persensitivity  per GSK 
adjudication
Serious Delay ed Acute Hy persensitivity  Reactions per GSK adjudication
Serious Delay ed Non -Acute Hy persensitivity  Reactions per GSK adjudication
8.2.2. Summary  Measure
8.2.2.1. Adverse Events of Special Interest
An overall summary  of AESI sby category  will be presented, and each specific category  
of AESI will be presented separately  by PT.  The number and percentage of subjects with 
at least one occurrence and the number of events wil l be present ed.  2018N381035_00
CONFIDENTIA L
BEL116027
33Infection AESI s that are serious, severe, serious/severe, and that lead to discontinuation 
will be presented b y category  and PT.
8.2.2.2. Post -infusion sy stemic reactions by  infusion
The number and percentage of subjects with at least one occurrenc e and the number of 
events will be present ed.
8.2.3. Population of Interest 
Theanalyses will be based on the ITTpopula tion.
8.2.4. Strategy  for Intercurrent (Post -Randomization) Events
For both endpoints, o bserved data will be used with no imputation .
8.2.5. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Secti on 8.2.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed.
8.3. Clinical Laboratory  Analyses
Laboratory  evaluations including the anal yses of chemistry  laboratory tests, hematolog y 
laboratory  tests, urinal ysis, and liver function tests will be based on GSK C ore Data 
Standards. The details of the planned display s are in Appendix 11: List of Data Display s.
An issue was identified at Q2 Solutions (central lab) i n Valencia, California, USA, 
regarding equipment malfunction which affected some serum creatinine results reported 
from one of the anal yzers used at the lab.  Unusually  high serum creatinine results were 
noted for two different GSK clinical trials, and fur ther investigation revealed one of the 
analyzers had been producing intermittent high serum creatinine results between 01 
October 2016 to 13 January  2017, potentially  due to an intermittent wash line blockage of 
the anal yzer.  BEL116027 investigators were notified of this issue by a Dear Investigator 
Letter (DIL) 22 February 2017 .  The subsequent evaluation concluded that there was n o 
impact on data integrit y and patient safet y for clinical trial BEL116027 .  Therefore, there 
will be no modification to the a nalysis of serum creatinine. BEL116027 investigators 
were notified b y a follow up DIL dated 25 July  2017, andthe root cause was identified as 
a sporadic failure of the wash system due to debris causing intermittent obstruction.
Baseline is defined as des cribed in Section 5.2.
A list of laboratory  parameters collected and definition of the toxicity  grades are provided 
in Appendix 8 : Values of Potential Clinical I mportance .
Listings will be generated for al l laboratory  results, and additionally  for Grade 3 or Grade 
4 laboratory  toxicity  results. 2018N381035_00
CONFIDENTIA L
BEL116027
34Line graphs will be produced for each anal yte display ing the mean value by  visit an d 
treatment group.
8.3.1. Endpoint / Variables
8.3.1.1. Clinical Laboratory  Results
Laboratory  parameters which are continuous numeric values will be anal yzed using 
summary  statistics, and those with categorical results will be summarized using 
frequencies and percentages.
8.3.1.2. Clinical Laboratory  Toxicity  Grades
The endpoints evaluated will be :
Worst toxi city grade
Worsening b y at least 2 toxicity  grades 
Toxicities will be reported as derived b y the central laboratory, as protocol toxicity  
grading was applied.
For potassium, glucose, calcium, and sodium, toxicities are bi -directional (i.e., high and 
low d irections) and both will be summarized by  name of the toxicity .
Potassium:  hy pokalemia, hy perkalemia
Glucose:  h ypoglycemia, hyperglycemia
Calcium:  hypocalcemia, hy percalcemia
Sodium:  hy ponatremia, hy pernatremia
For example, calcium will have two toxici ty sections, one for h ypocalcemia and one for 
hypercalc emia and mapped to their high or low form as:
RESUL T < (LLN+ULN)/2 = “Hy po” toxicity
RESUL T > (LLN+ULN)/2 = “Hy per” toxicity
8.3.1.3. Clinical Laboratory  Reference Range Shifts
For laboratory  tests without toxi city grades, shifts relative to the normal range will be 
summarized for each analy te as shifts ‘to low’ and shifts ‘to high.’
For the ‘to low category ’ the percentage of subjects with at least one low post -baseline 
value relative to the baseline (i.e. base line and post baseline data available) will be 
display ed using the categories:  no shift to low and normal/high to low. 
For the ‘to high category’ the percentage of subjects with at least one high post -baseline 
value relative to baseline (i.e. baseline an d post baseline data available) will be display ed 
using the categories:  no shift to high and normal/low to high.  2018N381035_00
CONFIDENTIA L
BEL116027
35A laboratory  value that is above the testing laboratory ’s normal range will be considered 
a high abnormal laboratory  value. A laboratory  valu e that is below the testing 
laboratory ’s normal range will be considered a low abnormal value.
8.3.1.4. Immunoglobulin Results Relative to the Lo wer Limit of Normal
Immunoglobulin s(IgG, IgA, IgM) will be classified relative to the reference range for the 
following cat egories:  < LLN and ≥LLN .
8.3.2. Summary  Measure
8.3.2.1. Clinical Laboratory  Results
Laboratory  parameters which are continuous numeric values will be anal yzed using 
summary  statistics, and those with categorical results will be summarized using 
frequencies and per centages. Results will be presented by  visit during the 52 -week 
treatment phase, and at any time post-baseline where specified.
8.3.2.2. Clinical Laboratory  Toxicity  Grades
The frequencies and percentages of subjects meeting each of the toxicity  grade endpoints 
will be summarized by visit during the 52 -week treatment phase, and at any time post-
baseline where specified .
8.3.2.3. Clinical Laboratory  Reference Range Shifts
The frequencies and percentages of subjects meeting each shift criteria will be 
summarized by  visit during the 52 -week treatment phase.
8.3.2.4. Immunoglobulin Results Relative to the Lo wer Limit of Normal
The frequencies and percentages of subjects who are <LLN and ≥LLN will be 
summarized by  visit during the 52 -week treatment phase.   The anal yses will be repeated 
forthe subgroup of patients who are ≥LLN and who are <LLN at baseline , respectivel y.
8.3.3. Population of Interest 
For all clinical laboratory endpoints, t he analyses will be based on the ITTpopulation.
8.3.4. Strategy  for Intercurrent (Post -Randomization) Events
For al l clinical laboratory endpoints, observed data will be used with no imputation.
8.3.5. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 8.3.1 will be
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed. 2018N381035_00
CONFIDENTIA L
BEL116027
368.4. Other Safety  Analyses
The anal yses of non -laboratory  safet y test results including immunogenicity and vital 
signswill be based on GSK Core Data Standards , unless otherwise specified. The details 
of the planned display s are presented in Appendix 11: List of Data Displays.
8.4.1. Endpoint / Variables
8.4.1.1. Immunogenicity
Serum samples for anti- belimumab antibody  measure ments will be obtained from 
subjects per the protocol
Fortheimmunogenicit y assessment, two ty pes of antibody  assay swill be performed, i.e. 
a bindin g assay  and neutralizing assay . For the binding assay , there will be 3- testing 
steps.  A screening assessment is performed which produces a result of positive or 
negative. For samples with a positive screening result, a confirmation assay is then 
carried out, which also produces a result of positive or negative. For samples with a 
positive confirmatio n result, a titer value will alsobeobtained to quantify  the degree of 
binding in a titration assay step. Patients will be viewed as positive for the binding assay  
if the confirmation assay  was positive. Subjects, who tested positive for the binding 
assay , will be tested for the neutralizing assay , which again produces a result of positive 
or negative . 2018N381035_00
CONFIDENTIA L
BEL116027
378.4.1.2. Vital signs
Vital signs will be collected per the protocol.   Parameters along with units for reporting 
are listed below.
Vital Sign Parameter
(Units )
Systolic Blood Pressure (sitting) (mmHg)
Diastolic Blood Pressure (sitting) (mmHg)
Heart Rate (beats/min)
Temperature (C)
Weight (kg)
BMI (kg / m2)
8.4.2. Summary Measure
8.4.2.1. Immunogenicity
Immunogenic response will be summarized by  visit and any time postbaseline for the 52 -
week treatment phase .
Categories of response are Negative, Transient Positive ( defined as a single positive 
response that does not occur at the fin al assessment, or Persistent Positive ( defined as a
positive response that occurs on at least 2 consecutive assessments or a single result at the 
final assessment).
8.4.2.2. Vital signs
Change from baseline in v ital signs will be presented using summary  statistics by visit .
Baseline bod y mass index (BMI) will be calculated from weight and height 
measurements.
BMI (kg/m2) =Weight (kg)
[Height (m)]2
BMI will be derived at each visit using the baseline value for height and the weight at the 
visit.  Since height is collected in centimeters (cm), it will be converted to meters (m) b y 
dividing by  100 before using it in the formula above.
8.4.3. Population of Interest 
For immunogenicity  and vital signs endpoints, the analyses will be based on the ITT
population.
8.4.4. Strategy  for Intercurrent (Post -Randomization) Events
8.4.4.1. Immunogenicity
Observed data will be used with no imputation. 2018N381035_00
CONFIDENTIA L
BEL116027
388.4.4.2. Vital signs
Observed data will be used with no imputation. I f weight or height is missing, then BMI 
will be missing.
8.4.5. Statistical A nalyses / Methods
Detai ls of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 8.4.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed.
8.5. Safet y Data for Maintenance Phase Subject Profile
AE data, grade 3 or 4 laboratory  data, and immunogenicity  data will be listed on the 
subject profile. 2018N381035_00
CONFIDENTIA L
BEL116027
399. PHA RMACOKINETIC ANAL YSES
9.1. Primary  Pharmacokinetic A nalyses
The primar y PK analysis will be of the serum belimumab concentrations.
9.1.1. Endpoint / Variables
Refer Section 13.5.3 Reportin g Standards for Pharmacokinetic.
9.1.2. Summary Measure
Descriptive statistics for serum belimumab concentrations willbe display edfor each 
visit. The tables will display the mean value, standard deviation, 95% CI of mean,
geometric mean, % CV, 95% CI of geometric mean, median, 25thand 75thpercentiles, 
minimum and maximum. 
9.1.3. Population of Interest 
The primary pharmacokinetic a nalyses will be based on the PKpopulation, unless 
otherwise specified.
9.1.4. Strategy  for Intercurrent (Post -Randomization) Events
Observed data will be used with no imputation .
9.1.5. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK data standards and statistical principles.
Unless otherwise specified, en dpoints / variables defined in Section 9.1.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed. 2018N381035_00
CONFIDENTIA L
BEL116027
4010. POPULA TION PHARM ACOKINETIC (POPPK) 
ANALYSES
Population Pharmacokinetic Anal ysisare not applicable to this study .   2018N381035_00
CONFIDENTIA L
BEL116027
4111. BIOM ARKER ANALYSES
11.1. Primary  Biomarker Analyses
11.1.1. Endpoint / Variables
Autoantibodies (anti -dsDNA, ANA), B LyS protein, B -cells ( CD19+, CD20+, 
CD20+/27+ memory , CD20+/27–naïve, CD20+/69+activated, 
CD20+/138+plasmacy toid, CD1 9+/27BRIGHT/38BRIGHT SLE subset and CD20 -/138+ 
plasma cells), immunoglobulins (IgG, IgA, and IgM), and complement (C3 and C4) will 
be assessed.   See Section 13.6.6.2 for additional details.
11.1.2. Summary  Measure
11.1.2.1. B-Cells
For the B -cells, the change and percent change from baseline in the original parent stud y
will be summarized at Weeks 0, 8, 16, 24, 32, 40 and 52 and from Week 24 to 32, Week 
24 to 40, and Week 24 to 52. 
11.1.2.2. Autoantibodies, Immunoglobulins and Complement
For autoantibodies, immunoglobulins and complement, the change and percent change 
from baseline in the original parent study  to each visit including the Day  0 visit in the 52 -
week treatment phase will be assessed.
Shifts from baseline in IgG, IgM, IgA, anti -dsDNA, ANA, C3 and C4.
11.1.2.3. BLyS Protein
The change and percent change from baseline in the original parent study  to each visit in 
the 52-week treatment phase will be assessed.
11.1.3. Population of Interest
For all endpoints in Section 11.1.1 , the primar y biomarker analyses will be based on the 
ITT po pulation .
11.1.4. Strategy  for Intercurrent (Post -Randomization) Events
For all endpoints in Section 11.1.1 , observed data will be used with no imputation .
11.1.5. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 11: List of Data Display sand 
will be based on GSK D ata Standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 11.1.1 will be
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed. 2018N381035_00
CONFIDENTIA L
BEL116027
4211.2. Biomarker Data for Maintenance Phase Subjects
By subject line plots for subjects who enter the maintenance phase for all visits fo r each 
B-cell parameter will be presented. 2018N381035_00
CONFIDENTIA L
BEL116027
4312. REFERENCES
Alarcón -Segovia D, Tumlin JA, Furie RA, et al for the L JP 394 I nvestigator Consortium. 
LJP 394 for the prevention of renal flare in patients with sy stemic lupus erythematosus. 
Arthritis Rheum. 2003;48( 2):442–54.
Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone 
hormone replacement therap y on disease activity in systemic lupus erythematosus: A 
randomized trial. Ann Intern Med 2005;142(12 Pt 1):953-62.
Cockcroft DW , Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron 1976;16:31-41.
Eibl MM, Rosen FS. I ntravenous gamma globulin and plasmapheresis. In: Frank 
MM,editor. Samter's Immunologic Diseases (5th ed.). Boston:Little, Brown, 1995:1529 -
36.
Goldfa rb NS, Avery  RK, Goormastic M, Mehta AC, Schilz R, Smedira N, Pien L , 
HaugMT, Gordon SM, Hague LK, Dresing JM, Evans- Walker T, Maurer 
JR.Hy pogammaglobulinemia in lung transplat recipients. Transplantation. 
2001;71(2):242 -6.
Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with 
systemic lupus ery thematosus. N Engl J Med 2005;353(24):2550 -8.
Yamini MH, Avery  RK, Mawhorter SD, Young JB, Ratliff NB, Hobbs RE, 
McCarth yPM, Smedira NG, Goormastic M, Pelegrin D, Starling RC. 
Hypogammaglobu linemiafollowing cardiac transplantation: a link between rejection and 
infection. J Heart Lung Transplant. 2001;20(4):425 -30. 2018N381035_00
CONFIDENTIA L
BEL116027
4413. APPENDICES
13.1. Appendix 1: Protocol Deviation 
See Section 4.1for details. 2018N381035_00
CONFIDENTIA L
BEL116027
4513.2. Appendix 2: Schedule of A ctivities
13.2.1. Protocol Defined Schedule of Events
13.2.2. Time and Events Table (Year 1)
Screen Treatment Holiday Study Follow -up
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 -- --
Study DayUp to 
-30 1 0 228 
7d56 
7d84 
7d112 
7d140
7d168 
7d196
7d224 
7d252 
7d280
7d308 
7d336 
7d364  7d or 
Exit16-wk 
7d 36 mo 
7d
Study Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 -- --
Written Informed Consent 4 X
Demography X
Medical History X
SLE History X
Therapy History X
Physical Examination X
Inclusion/Exclusion X
Efficacy Assessments
DAS: SS, SLE Flare Index, 
PGA 5X 1
X X X X X X X X X X X X X X
SLICC/ACR Damage Index X X X
Safety Assessments
Vital Signs 6 X X X X X X X X X X X X X X X
Weight, height 6, 7 X X X X X X X X X X X X X X
Symptom -driven Physical 
ExamX X X X X X X X X X X X X X X
Record Concurrent 
MedicationsX X X X X X X X X X X X X X X
Adverse E vents X X X X X X X X X X X X X X X
Laboratory Assessments
Haematology & Modified 
Chem 20 (non- fasting) 6XX X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X X X
Spot urine (protein to X X X X X X X X X X X X X X X 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
46Screen Treatment Holiday Study Follow -up
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 -- --
Study DayUp to 
-30 1 0 228 
7d56 
7d84 
7d112 
7d140
7d168 
7d196
7d224 
7d252 
7d280
7d308 
7d336 
7d364  7d or 
Exit16-wk 
7d 36 mo 
7d
Study Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 -- --
creatinine ratio) 8
Pregnancy Test 6, 9 U U U U U U U U U U U U U U U U
Pharmacogenetic Sampling 10 X
aCL Autoantibody X X
C3/C4 X X X X X X X X X X X X X X X
Anti-dsDNA Autoantibodies X X X X X X X X X X X X X X X
ANA Autoant ibodies X X X
IgG, IgA & IgM 11 X X X X X X X X
PT/ PTT X
Exploratory Lab Assessments
Pharmacokinetic Sampling 12 X X X X 12 X X 12
Immunogenicity6, 13 X X X 13 X X X X X 13
BLyS Protein 14 X X X
B cell Markers 15 X X X X X X X X
Investigational Product (IP)
IP Administration16 X X X X X X X X X X X X X X
1. DAS = disease activity scales; SS = SELENA SLEDAI; SLE = systemic Lupus Erythematosus; PGA = Physician’s Global Assessment; SLICC/ACR = Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology; ALT = alanine aminotransaminase; AST = aspartate aminot ransaminase; PT/PTT = prothrombin time/partial 
thromboplastin time; BlyS = B Lymphocy te Stimulator; IP = investigational product; aCL = anticardiolipin
2. A screening visit of up to 30 days prior to the Day 0 visit will be scheduled for subjects in the treatment holiday and contr ol groups for assessment of SELENA SLEDAI score to 
assess eligib ility.
3. The EXIT Visit in the respective feeder continuation studies will serve as the Day 0 visit for all 3 subject groups in this s tudy. Assessments covered for both this study at Day 0 
and the Exit visit of the feeder continuation studies need only be pe rformed once and recorded in the appropriate case report forms for each study. Subjects in the control group 
must be able to receive the 1stdose of belimumab on Day 0 of this study on average 4 weeks (minimum of 2 weeks, maximum of 8 weeks) after the last dose in the feeder 
continuation study.
4. The 16 week follow -up visit will occur at approximately 16 weeks after last dose of investigational product for subjects in the control group wh o withdraw at any time during the 
study, or for subjects in the treatment holiday group who withdraw from the study from Week 24 onwards (Visit 7) during the belimumab re -introduction period. The 16 -week and 6 
month follow -up visits do not apply to subjects in the long -term discontinuation group. 
5. Obtain written informed conse nt to participate in this study at the Screening visit. 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
476. Guidelines for scoring proteinuria for SELENA SLEDAI are provided in protocol Section 6.3.1.1 .
7. Complete assessment prior to belimumab dosing for subjects in the control group (to Week 48) and for sub jects in the treatment holiday group (during Weeks 24 to 48 or earlier in 
the event of a flare).  Immunogenicity testing includes quantifying the amount of belimumab present in the samples using the belimumab PK assay.
8. For any subject whose weight changes by more than 5% from that recorded at Day 0, use the weight at the current visit for calculating the belimumab dose to be adm inistered. 
Height measured only at Day 0.
9. A 24-hour urine may be done as an additional assessment if clinically indicated (e.g., r enal flare).
10. Urine pregnancy test results for women of child -bearing potential must be available prior to dosing (during Weeks 0 to 48 in the control group and during Weeks 24 to 48 or e arlier 
in the event of a flare in the treatment holiday group).Can be performed at any time during the visit for females of child -bearing potential in the long -term discontinuation group.
11. PGx sampling from consenting subjects recruited from all studies except from study BEL114333. PGx informed consent must be ob tained prior to sampling.
12. Serum immunoglobulin isotypes: IgG, IgM, IgA.
13. Pharmacokinetic sampling at select sites for subjects in the control and treatment holiday groups; subjects in the treatment holiday group can have PK sampling performed at any 
time during the visi t between Weeks 0 and 16.  Otherwise, if on a dosing day, sampling must be performed prior to dosing. Collect blood samples pre -dose and post -dose at the 
end of the infusion at Weeks 24 and 52 (or earlier if belimumab is re -started before Week 24 in the ev ent of a severe flare by using the escape option).   Subjects in the long -term 
discontinuation group will have one PK sampling performed at any time during the visit between Weeks 0 and 24.  PK sampling f or the long- term discontinuation group is not 
perfor med after Week 24.  Long -term discontinuation subjects withdrawing before Week 24 will have one PK sampling performed at any time during the EXIT visi t.   PK sampling 
for long -term discontinuation subjects withdrawing after Week 24 is not performed at the EXIT visit.
14. Blood sample for immunogenicity will be taken at Weeks 12, 24, 36 and 52 for all three groups.  In addition, a blood sample f or immunogenicity will also be taken 4 weeks prior
to the reintroduction of belimumab (at Week 20 since belimumab will be reintroduced at Week 24) in the treatment holiday group. A blood sample for immunogenicity must be 
taken at least 6 months after the final dose of investigational product for any subjects in the control group or treatment ho liday group who had an anti -belimumab antibody 
response at the 16 -week follow -up visit (or at the last immunogenicity assessment if 16 -week follow -up is not available). Note that serum samples for immunogenicity must be 
collected pre -dose at the time of dosing from subjects in the tre atment holiday group who experience a severe flare prior to Week 24 and consequently receive open -label 
belimumab as rescue.  Immunogenicity blood sample will not be collected at the 6 -month follow up visit for subjects in the long -term discontinuation gro up as this visit does not 
apply to this subject group.
15. Measured in treatment holiday group at Weeks 16 and pre -dose at Week 24. Measured in long -term discontinuation group at Weeks 16, 24 and 32. Not measured in control 
group.
16. Biological Markers include FA CS of peripheral lymphocytes: B lymphocytes (CD20+, CD20+/27+ memory, CD20+/27 –naïve, CD20+/69+ activated, CD20+/138+ plasmacytoid, 
CD19+/27BRIGHT /38BRIGHT SLE subset and CD20 -/138+ plasma cells). Note: B cell markers will not be collected at the 6 -month follow up visit for subjects in the long -term 
discontinuation group as this visit does not apply to this subject group.
17. Only subjects in the control group will receive belimumab 10 mg/kg during Weeks 0 through 20 inclusive;  subjects in the cont rol group m ust be able to receive the first dose of 
belimumab in this study 4 weeks (minimum of 2 weeks, maximum of 8 weeks) after the last dose in their previous open- label continuation study  Subjects in the control group 
and treatment holiday groups will receive b elimumab from Weeks 24 through 48 although subjects in the treatment holiday group may be treated with belimumab prior to Week 
24 as determined by the investigator in the event of increased SLE activity. When belimumab therapy is re -started, subjects in th e treatment holiday group will remain under 
clinical supervision for 3 hours after completion of the first 2 infusions. At the Week 52 visit, only subjects in the treatment holiday and control groups who are continuing 
belimumab therapy beyond this time wi ll be dosed. 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
4813.2.3. Time and Events Table (A dditional Years)
Study Visit (Weeks) 1 4 8 12 16 20 24 28 32 36 40 44 48
Study Day28   
7d56   
7d84   
7d112 
7d140 
7d168 
7d196 
7d224 
7d252 
7d280 
7d308 
7d336 
7d
Efficacy Assessments
Disease Activity Scales: SELENA SLEDAI, 
SLE Flare Index, and PGA 2X X
SLICC/ACR Damage Index X
Safety Assessments
Symptom -driven Physical Exam X X
Record Concurrent Medications X X X X X X X X X X X X
Advers e Events X X X X X X X X X X X X
Vital Signs 3, 4 X X X X X X X X X X X X
Laboratory Assessments
Haematology & Modified Chem 20 (non -
fasting) 3, 5X X
Urinalysis 5, 6 X X
Spot urine (protein to creatinine ratio) 3,5, 6 X X
Urine Pregnancy Test3, 5, 7 X X X X X X X X X X X X
C3, C4, Anti -dsDNA Autoantibodies 3, 5 X X
IgG 3,5,  8 X
IgA & IgM 3, 5, 8 X
Exploratory Lab Assessments
Immunogenicity3 ,9 X X
B cell Markers 10 X
Investigational Product
Belimumab  Administration 4, 11 X X X X X X X X X X X X 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
491. Calendar represents a yearly (48 -week) ongoing visit schedule until the subject is terminated from the study.
2. Guidelines fo r scoring proteinuria for SELENA SLEDAI are provided in protocol Section 6.3.1.1 .
3. Assessments performed prior to dosing.
4. For any subject whose weight changes by more than 5% from that recorded at Day 0, use the weight at the current visit for cal culating the belimumab dose to be administered.
5. During “Additional years”, investigators can obtain any of the same laboratory assessments that are mentioned for Year 1 (hae matology, modified Chem 20, urinalysis, spot urine 
to creatinine ratio, urine pregnancy, C3, C4, anti -ds DNA autoantibodies, IgG, IgA, and IgM), as unscheduled laboratory tests at any time during Year 2 and beyond, if clinicall y 
indicated.  Any additional laboratory tests beyond this, if not related to the protocol, will be the responsibility of t he investigator and subject.
6. A 24-hour urine may be done as an additional assessment if clinically indicated (e.g., renal flare). 
7. Results of urine pregnancy tests in women of child -bearing potential must be available prior to belimumab dosing.
8. Serum immun oglobulin isotypes: IgG, IgM, IgA.
9. Immunogenicity testing includes quantifying the amount of belimumab present in the samples using the belimumab PK assay.
10. Biological Markers include FACS of peripheral lymphocytes: B lymphocytes (CD20+, CD20+/27+ memory, C D20+/27 –naïve, CD20+/69+ activated, CD20+/138+ plasmacytoid, 
CD19+/27BRIGHT/38BRIGHT SLE subset and CD20 -/138+ plasma cells).
11. After completion of the Week 48 visit during year 1 of the study, subjects in the treatment holiday and control groups can co ntinue to receive belimumab therapy at 4 -weekly 
intervals in the maintenance phase of this study. Subjects who withdraw from belimumab therapy during this maintenance phase will complete the Exit and follow -up visits detailed 
in the Year 1 Time and Events Tabl e. The Exit visit Schedule should be scheduled 4 weeks after the final belimumab dose and the 16 -week follow -up visit 16 weeks after the final 
belimumab dose. 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
5013.3. Appendix 3: A ssessment Windows
13.3.1. Mapping of the Maintenance Phase Visits for Subjects with an 
Escape Visit
In the eCRF, the next visit provided following the Escape visit is the Year 2 Week 8 visit, 
when chronologically  the next visit would be the Year 2 Week 4 visit.  Therefore, the
maintenance phase visits for subjects with an Escape visit will be r e-mapped in the 
ADaM analy sis data sets to the maintenance phase visit, so that the visits align
chronologicall ywith those for subjects who complete the 52 -week treatment phase and 
subsequently  enter the maintenance phase .
If an Escape visit is present, mapping will occur as follows:
SDTM Variable ADAM Variable
Domain VISITNUM
VISITAVISITN
AVISIT
All 190
ESCAPE190
ESCAPE
All 220
YEAR 2 WEEK 8210
YEAR 2 WEEK 4
All 230
YEAR 2 WEEK 12220
YEAR 2 WEEK 8
All 240
YEAR 2 WEEK 16230
YEAR 2 WEEK 12
The mapping will continue in this pattern for subsequent visits.
13.3.2. Mapping of Week 16 and 6 -month Follow -up Visits
The 16-week and 6 -month follow -up visits will be re -mapped in the ADaM anal ysis data 
sets so that they  sort in chronological sequence when using the numeric visit number. 2018N381035_00
CONFIDENTIA L
BEL116027
51SDTM Variable ADAM Variable
Domain VISITNUM
VISITAVISITN
AVISIT
All 170
16 WK FOLLOW -UP9100
16 WK FOLLOW -UP
All 180
6 MO FOLLOW -UP9200
6 MO FOLLOW -UP
13.3.3. Analysis Visit and A nalysis Visit Number
The data are anal yzed according to the planned visit assignment in the data.  
Exit/withdrawal visits must be slotted to the appropriate planned visit according to the 
study  phase. This will only  be done for subjects that withdrew earl y and did not complete 
the 52- week trea tment phase . Unscheduled laboratory  visits will also be slotted to the 
appropriate planned visit. 
The Anal ysis Visit is assigned based on the interval in which the Study  Day  for the 
exit/withdrawal visit or unscheduled laboratory visit falls according to intervals 
(inclusive) provided below. For completeness, the table also includes visits which are not 
slotted; these visits will have ‘na’ for ‘not available’ listed for the Interval Start and End 
Day.
Analysis VisitAnalysis 
Visit Number Target Study Day1Interval Start Day Interval End Day
Screening 10 -34 na na
52-week Treatment Phase visits:
Baseline 20 1 na na
Week 4 30 29 22 42
Week 8 40 57 43 70
Week 12 50 85 71 98
Week 16 60 113 99 126
Week 20 70 141 127 154
Week 24 80 169 155 182
Week 28 90 197 183 210
Week 32 100 225 211 238
Week 36 110 253 239 266
Week 40 120 281 267 294
Week 44 130 309 295 322
Week 48 140 337 323 350
Week 52 150 365 351 378 2018N381035_00
CONFIDENTIA L
BEL116027
52Analysis VisitAnalysis 
Visit Number Target Study Day1Interval Start Day Interval End Day
1Day 0 visit date in study 116027 =Study Day 1.
13.3.4. Windows for A ssessment of Post -injectio n/infusion sensitivity  
reactions (PISR) and hypersensitivity reactions (HSR)
The windows for assessment of PISR/HSR, as described in the AESI definitions in 
Section 13.9.2 , are as follows:
Date of Infusion
Day 1 Day 2 Day 3
SMQ narrow, broad and algorithmic searches (On day  of injection/infusion or within 3 
days of injection/infusion) 2018N381035_00
CONFIDENTIA L
BEL116027
5313.4. Appendix 4: Stud y Phases and Treatment Emergent 
Adverse Events
13.4.1. Treatment Phases
Visits, a ssessments and events will be classified according t o the time of occurrence 
relative to the following cut-point dates for each treatment group.
For convenience and ease of data presentation, the 52- Week Treatment Phase has the 
same name designation for all three treatment groups, even though the LTC group 
does not receive treatment at all during this phase and the TH group receives 
treatment for onl y the second half of the phase.
Only  the TC and TH groups are eligible to participate in the Maintenance Phase.
If an AE start date falls on the Day  0 date, then it will be considered treatment 
emergent (i.e., fall in the 52 -week treatment phase).  If a concomitant medication 
start date falls on the Day  0 visit date, the concomitant medication will be considered 
to fall in the 52- week treatment phase. An y other as sessments that fall on the Day  0 
visit date will be considered to occur in the pre -study  phase .
For the TC group, if the first infusion date differs from the Day  0 visit date, then the 
first infusion date will be used as the phase cut- point.
Other than Day 0, if an assessment or event occurs on the same date as a phase cut -
point, then the event will be considered to fall in the previous phase.  For example, if 
a new prednisone dose starts on the same date as the Week 24 visit date and then 
continues for a t otal of 7 days, then the first day  of that prednisone dose will fall into 
the Holiday  Phase and the remaining 6 will fall into the Re -start phase.
For AEs, i f the AE Onset date is missing, then the AE will be considered to occur in 
the 52- week treatment ph ase.
For the TH group, a subject who re -starts treatment prior to Week 24 will not have a 
Re-Start phase. 2018N381035_00
CONFIDENTIA L
BEL116027
5413.4.1.1. Treatment Holiday  Group
EndpointDay 0 Visit
Parent 
StudyDay 0 Visit
BEL116027 
StudyWeek 24/
TX Re -start 
VisitWeek 52/
Exit/Escape 
VisitWeek 
16 
Follow -
up Visit
Baseline
Flare, PGA, Prednisone, 
SLICC N/A52-Week Treatment Phase Maintenance 
PhaseN/AHoliday Phase Re-start Phase
Baseline
SS, Auto -antibodies 
Immunoglobulins, 
B-cells [1], BLySPre-Study 
Phase52-Week Treatment PhaseMaintenan ce 
PhaseN/A
Holiday Phase Re-start Phase
Baseline
Rebound [2]Pre-Study 
Phase52-Week Treatment Phase
N/A N/A
Holiday Phase N/A
Baseline
Adverse Events, Lab 
Parameters, Vital Signs, Con 
Meds  Immunogenicity [1]N/A52-Week Treatment PhaseMaintenance 
PhaseN/A
Holiday Phase Re-start Phase
N/A= Not Applicable.
[1] Immunogenicity and B -cells may also be collected at the 6 -month follow- up visit.  The 6 -month follow- up 
visit is not represented in the diagram since it does not define a trea tment phase of the study.
[2] Rebound is only assessed up to the Week 24/Treatment re -start visit. 2018N381035_00
CONFIDENTIA L
BEL116027
5513.4.1.2. Treatment Control Group
EndpointDay 0 Visit
Parent StudyDay 0 Visit
BEL116027 
Study [1]Week 24 VisitWeek 52/
Exit VisitWeek 
16 
Follow
-up 
Visit
Baseli ne
Flare, PGA, Prednisone, 
SLICCN/A 52-Week Treatment PhaseMaintenance 
PhaseN/A
Baseline
SS, Auto -antibodies 
Immunoglobulins, 
B-cells [2], BLySPre-Study 
Phase52-Week Treatment PhaseMaintenance 
PhaseN/A
Baseline
Rebound [3] 52-Week Treatment P hase
Pre-Study 
PhaseFirst 24 Weeks N/A N/A N/A
Baseline
Adverse Events, Lab 
Parameters, Vital Signs, Con 
Meds , Immunogenicity [2]N/A 52-Week Treatment PhaseMaintenance 
PhaseN/A
N/A = Not Applicable.
[1] If the first infusion date differs from th e Day 0 visit date, then the first infusion date will be used as the 
phase cut -point.
[2] Immunogenicity and B -cells may also be collected at the 6 -month follow- up visit.  The 6 -month follow- up 
visit is not represented in the diagram since it does not defi ne a treatment phase of the study.
[3] Rebound is only assessed up to the Week 24 visit. 2018N381035_00
CONFIDENTIA L
BEL116027
5613.4.1.3. Long -term Discontinuation Group
EndpointDay 0 Visit
Parent 
StudyDay 0 Visit
BEL116027 StudyWeek 24 VisitWeek 52/
Exit Visit
Baseline
Flare, PGA, Prednisone, 
SLICCN/A N/A52-Week Treatment 
PhaseN/A
Baseline
SS, A uto-antibodies 
Immunoglobulins , BLySN/A Pre -Study Phase52-Week Treatment 
PhaseN/A
Baseline
Rebound
N/A Pre -Study Phase52-Week Treatment 
PhaseN/AFirst 24 
WeeksN/A
Baseline
Advers e Events , Lab 
Parameters, Vital Signs ,
Con Meds N/A N/A52-Week Treatment 
PhaseN/A
N/A = Not Applicable. 2018N381035_00
CONFIDENTIA L
BEL116027
57Treatment 
StateTreatment 
GroupDefinition
Treatment 
EmergentTH, LTD AE Onset Date ≥ Day 0 visit date
Treatment 
EmergentTC AE Onset Date ≥ Date of First Infusion in BEL116027
Onset Time 
Since 1st
Dose (Days)TH, TC If Date of First Infusion in BEL116027 ˃AE Onset Date:
= AE Onset Date -Date of First Infusion in BEL116027
If Date of First Infusion in BEL116027 ≤ AE Onset Date
= AE Onset Date -Date of First Infusion in BEL116027+1
=Missing otherwise.
Onset Time 
Since Study 
Start (Days)TH, TC, LTD If Day 0 visit date ˃AE Onset Date:
= AE Onset Date –Day 0 visit date
If Day 0 visit date ≤ AE Onset Date
= AE Onset Date -Day 0 visit date +1
=Missi ng otherwise.
Duration 
(Days) TH, TC, LTD AE Resolution Date –AE Onset Date + 1
Drug -related TH, TC, LTD If relationship is marked ‘YES’ on Inform/CRF OR value is missing.
1. NOTES:
 If the AE Onset date is missing, then the AE will be considered as treat ment emergent. 2018N381035_00
CONFIDENTIA L
BEL116027
5813.5. Appendix 5: Data Display  Standards & Handling 
Conventions
13.5.1. Reporting Process
Software
The currently supported versions of SAS software will be used .
Reporting Area
HARP Server US1SALX00259
HARP Compound
and Reporting effortGSK1550188 /BEL116027/final_01
Analysis Datasets 
Analysis datasets will be created according to CDISC standards (SDTM IG Version 3.2 & ADaM IG 
Version 1.0).
Generation of RTF Files
RTF files will be generated for all tables in the final_cdisc RE
13.5.2. Reporting Standa rds
General
The current GSK Integrated Data Standards Library (IDSL) will be applied for reporting , unless 
otherwise stated (IDSL Standards Location: https://spope.gsk.com/sites/ID SLLibrary/SitePages/Home.aspx ):
4.03 to 4.23: General Principles
5.01 to 5.08: Principles Related to Data Listings
6.01 to 6.11: Principles Related to Summary Tables
7.01 to 7.13: Principles Related to Graphics 
Do not include subject level listings in th e main body of the GSK Clinical Study Report. All subject level 
listings should be located in the modular appendices as ICH or non -ICH listings
Formats
GSK IDSL Statistical Principles (5.03 & 6 .06.3) for decimal places (DP’s) will be adopted for reportin g of 
data based on the raw dat a collected , unless otherwise stated.
Numeric data will be reported at the precision collected on the eCRF.
The reported precision from non eCRF sources will follow the IDSL statistical principles but may be
adjust ed to a clinically interpretable number of DP’s .
Planned and Actual Time
Reporting for tables, f igures and formal s tatistical analyses:
Planned time relative to dosing will be used in figures, summaries, statistical analyses and 
calculation of any derived parameters , unless otherwise stated.
The impact of any major deviation from the planned assessment times and/or scheduled visit days 
on the analyses and interpretation of the results will be assessed as appropriate .
Reporting for Data Listings: 
Planned and actual t ime relative to study agent dosing will be shown in listings (Refer to IDSL 
Statistical Principle 5.05.1).
Unscheduled or unplanned readings will be presented within the subject’s listings. 
Unscheduled Visits
Unscheduled visits will not be included in s ummary tables.
Unscheduled visits will be included in figures unless their inclusion contributes adversely to  2018N381035_00
CONFIDENTIA L
BEL116027
59visual presentation or interpretation of the figure .
All unscheduled visits will be included in listings.
Descriptive Summary Statistics
Continu ous Data Refer to IDSL Statistical Principle 6.06.1
Categorical Data N, n, frequency, %
Graphical Displays
Refer to IDSL Statistical Principals 7.01 to 7.13.
13.5.3. Reporting Standards for Pharmacokinetic
Pharmacokinetic Concentration Data
Descriptive 
Summar y Statistics 
(Log Transformed)N, n, geometric mean, 95% CI of geometric mean, standard deviation (SD) 
of log transformed data and between geometric coefficient of variation (CVb 
(%)) will be reported.
CVb(%) = √ (exp(SD2) -1) * 100
(SD = SD of log trans formed data) 
Parameters Not 
Being Log 
TransformedN, n mean, 95% CI, standard deviation (SD), median, 25thand 75th
percentile, minimum and maximum will be reported.
Pharmacokinetic Parameter Data
Is NQ impacted PK 
Parameters Rule 
Being FollowedYes, refer to Standards for Han dling NQ Impacted PK Parameters 2018N381035_00
CONFIDENTIA L
BEL116027
6013.6. Appendix 6: Derived and Transformed Data
13.6.1. General
Multiple Measurements at One Time Point
Mean of the measurements will be calculated and used in any derivation of summary statistics 
but if liste d, all data will be presented.
Subjects having both High and Low values for Normal Ranges at any post -baseline visits for 
safety parameters will be counted in both the High and Low categories of “Any visit post -
baseline” row of related summary tables. This will also be applicable to relevant Potential 
Clinical Importance summary tables.
Study Day
Calculated as the number of days from the Day 0 Visit Date (i.e., Day 1) to the assessment 
date or visit date of interest (Ref Date)
Ref Date = Missing             → Study Day = Missing 
Ref Date < Day 0 Visit Date   → Study Day = Ref Date – Day 0 Visit Date    
Ref Data ≥Day 0 Visit Date    → Study Day = Ref Date –Day 0 Visit Date + 1
13.6.2. Study Population
Demographics
Study Phases Definitions for Disposition
Compl etion/withdrawal for the 52 -Week Treatment Phase will be derived as follows:
oWithdrawn if the subject completion status is marked as No and the subject has no 
visits during the maintenance phase.
oComplete if the subject completion status is marked as Yes a nd the subject has no 
visits during the maintenance phase.
Completion/withdrawal for the Maintenance Phase will be derived as follows:
oWithdrawn if the subject completion status is marked as No and the subject has at 
least one visit during the maintenance phase.
oComplete if the subject completion status is marked as Yes and the subject has at 
least one visit during the maintenance phase.
Age
GSK standard IDSL algorithms will be used for calculating age where birth date will be imputed 
as follows:
oAny sub ject with a missing day will have this imputed as day ‘15’. 
oAny subject with a missing date and month will have this imputed as ‘30th June’.
Birth date will be presented in listings as ‘YYYY’.
Analysis age is derived in years relative to the Day 0 visit d ate, and is calculated in SAS as 
follows:
Analy sis Age (y ears) 
=INTCK('y ear', Date of Birth, Day  0 Date) 
-  (  MONTH(Day  0 Date) < MONTH(Date of Birth)  2018N381035_00
CONFIDENTIA L
BEL116027
61Demographics
      or (MONTH(Day  0 Date) eq MONTH(Date of Birth) 
             and DAY(Day  0 Date) < DAY(Date of B irth)  )  )
Proteinuria
For analysis, urine protein in g/24 -hour will be approximated by the urine protein:creatin ine ratio 
(uPCR) .
The value for reporting and analysis is stored in the uPCR result variable corresponding to the 
original unit in the SI dataset. Depending on the study, units for uPCR may be reported in g/g or 
mg/mg.  A s long as the units are the same in the numerator and denominator, the ratio will be 
the same.  
The SI dataset standard unit is reported in mg/mmol is not used for reporti ng and analysis 
purposes in this study .
Concomitant medications
Concomitant medications are defined as 
a.Medications that start on or before the Day 0 visit date and end on or after the Day 0 visit 
date, or 
b.Medications that start after the Day 0 visit d ate
Medications that meet criterion ‘a’ are considered to be in use at baseline. 
Medications will be assigned to the 52 -week treatment or maintenance phases, as per the 
definitions in Section 13.4.1 .
Medications with partial o r missing start and/or stop dates will be assumed to be concomitant 
unless there is evidence through comparison of partial dates to suggest otherwise, for example 
if the day is missing, then the month and year will be compared to the month and year of the 
first dose date of study treatment and if the month and year are the same or later, then the 
medication will be considered concomitant.
Allowable SLE Medications at Baseline
There are 5 medication categor ies that are evaluated .  These medication categor ies are defined in the table 
below and stored in the variable CM SCAT.  Only medications providing systemic exposure are evaluated .  
Systemic exposure is based on the route of administration.  A flag variable for systemic exposure when 
CMSCAT is not blank i s defined below and stored in the variable SY STEMIC.  The medication must have 
one of the defined medication categories below (CM SCAT ne blank) and must provide systemic exposure 
(SYSTEMIC=’Y’).   
Medication Category (CMSCAT) Rule
Anti-malarials Set CMSCAT to "ANTIMALARIALS" if the preferred 
term begins with "QUINACRINE", "QUININE", 
"HYDROXYCHLOROQUINE",
"MEPACRINE", or "CHLOROQUINE" 
Steroids Set CMSCAT to ‘STEROIDS’ if at least one 
associated ATC code (ATCCD1 –ATCCD6) begins 
with ‘H02’  2018N381035_00
CONFIDENTIA L
BEL116027
62Allowable SLE Medications at Baseline
Immunosuppre ssants Set CMSCAT to ‘IMMUNOSUPPRESSANTS’ if at 
least one associated ATC code (ATCCD1 –
ATCCD6) begins with ‘L04A’ or the preferred term 
begins with “CYCLOPHOSPHAMI DE”or 
“MERCAPTOPURINE”.
NSAIDs Set CMSCAT to NSAIDs if at least one associated 
ATC code ( ATCCD1 –ATCCD6) begins with ‘M01A’.
Aspirin Set CMSCAT to "ASPIRIN" if CMDECOD contains 
"ACETYLSALICYLIC ACID" or 
"ACETYLSALICYLATE LYSINE".
Prohibited Set to "PROHIBITED" if any of
the following conditions are met, if CMDECOD 
equals "INVESTIGATIONAL DR UG", 
"IMMUNOGLOBULIN",
"ADALIMUMAB", "ETANERCEPT", "INFLIXIMAB", 
"RITUXIMAB", "ABATACEPT", "ANAKINRA",
"GOLIMUMAB", "CERTOLIZUMAB" 
and/or 
A review of the surgeries/procedures form indicates 
the subject had "PLASMAPHERESIS".
Traditional Chinese medicatio ns Glycosides of 
Paeony and TripterygiumThese medications will be identified based on a 
clinical review of all the concomitant medications 
assigned the following drug collection codes in the 
GSK drug dictionary:  50119401, 54654601, 
40987301, 50192401, 5 3020201, 53060901, 
53766001, 53927401, 53959101, 53959201, 
53990601, 54619401, 54731901, 54908201, 
59164101
Systemic (SYSTEMIC) Rule
Blank If CMSCAT =blank
Y ‘Y’ if CMSCAT ne blank and the route of 
administration is "INTRADERMAL ”“PO” 
"INTRAMUSCULAR", " INTRAVENOUS", "ORAL", or 
"SUBCUTANEOUS" 
N ‘N’ otherwise and CSMCAT ne blank
Treatment Compliance
Treatment compliance for patients completing the 52 week treatment phase or withdrawals is 
calculated as:
Prescribed number of infusions will be 7 for t he TH arm and 13 for the TC arm, except for TH subjects 
who escape to the Maintenance Phase.  For TH subjects who escape, the treatment compliance will be 
missing. The Week 52 infusion is considered to be the first infusion of the maintenance phase.
NB: fo r withdrawals the  number of infusions prescribed is the number  from Day 0 up to the withdrawal 
date 2018N381035_00
CONFIDENTIA L
BEL116027
63Extent of Exposure
Number of days of exposure to study treatment during the 52 -week Treatment Phase will be 
calculated based on the formula:  
Duration of Exposure in Days = (Date of last infusion in BEL116027 52-week treatment 
Phase –Date of first infusion in BEL116027) + 28
The Week 52 infusion is considered to be the first infusion in the Maintenance Phase, and will 
not be considered in this calculati on.
Subjects who were enrolled in the TH and TC groups but did not receive an infusion will be 
categorised as having zero days of exposure. 
Exposure will not be calculated for the LTD group.
Only complete dates will be used when calculating duration of ex posure.  
Exposure will not be adjusted for skipped infusions.
13.6.3. Efficacy
SLEFlares and Severe Flares , and Renal Flares
Baseline Flares
Baseline flares will be summarized using the data from the eCRF SFI data collection 
for the Day  0 visit.  Per eCRF com pletion guidelines, the data collected at the Day  0 
visit represents the flare data since the previous visit (i.e. the last visit in the feeder 
continuation study ). 
SLE Flares and Severe SLE Flares 2018N381035_00
CONFIDENTIA L
BEL116027
64SLEFlares and Severe Flares , and Renal Flares
SFI reports the first mild /moderate or severe fl are occurrence since the last visit 
assessment.  
The SL EDAI criteria will be assessed programmatically  to determine if the SEL ENA 
SLEDAI criteria for a flare has been met and used for the assessment of flare, 
irrespective of what was recorded on the SFI f orm.  
Although there are boxes on the form for the investigator to classify the most recent 
flare to mild/moderate or severe, the classification will be re -derived from the 
subcategory  scores. Flares originall y marked severe will be downgraded to “Not 
Severe” if the onl y reason marked is a change in SEL ENA SLEDAI score to > 12.  
In this case, if an y of the mild/moderate reasons are checked or if the modified 
SELENA SLEDAI score has a change from previous visit of at least 3, then the flare 
will be conside red Mild/Moderate.
Flares that are marked mild/moderate where the only  reason checked is SELENA 
SLEDAI increase of at least 3 points but not more than 12 points will be re -derived 
using the modified SELENA SL EDAI score.  
If it’s found that the change is n ot actually  ≥ 3, and no other reasons are checked,  2018N381035_00
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by
third party copyright laws and therefore have been excluded.
CONFIDENTIA L
BEL116027
65SLEFlares and Severe Flares , and Renal Flares
then the flare will not be counted .
Renal Flares
A SL E Renal flare is defined as the occurrence of at least 1 or more of the following in 2 
or more consecutive visits during the stud y.(NB: at least 1 o f the same criteria must be 
present on at least 2 consecutive visits)
Increased Proteinuria (using spot urine)
A reproducible increase in 24 -hour urine protein levels (as measured in uPCR) to:
>1g if the baseline (Day  0)value was <0.2g  
OR
>2g if the base line (Day  0) value was between 0.2g and 1g
OR
More than twice the value at baseline (Day  0) if the baseline value (Day  0)was >1g
Impaired Renal Function
A reproducible decrease in GFR of >20%, accompanied b y proteinuria (>1), and/or 
cellular (RBC and WBC) casts.
 [Alarcón -Segovia ,2003].
GFR is estimated by  the Cockcroft -Gault equation [Cockcroft , 1976] for creatinine 
clearance in mL/min.
Cockcroft -Gault Equation
Clcr(mL/min) =(140-age (yrs)) x wei ght (kg)
x 0.85 if female
72 x serum creatinine (mg/dL)
“Reproducible” requires the criterion to be met at two consecutive visits, including 
unscheduled visits.
The following table identifies the lab parameters to be used to evaluate the criteria in th e 
renal flare definition above.  
Criterion ParameterSI Dataset 
LBTESTCD
Proteinuria Urine Protein:Creatinine Ratio (mg/mg) PRTCRT_URQ
GFR Creatinine Clearance estimated by the 
Cockcroft -Gault equation (mL/min)CRTCE_PLR
Cellular casts:
WBC cellula r casts WBC cellular casts WBCSTM_URQ
dysmorphic RBCs dysmorphic RBCs DRBCM_URQ 2018N381035_00
CONFIDENTIA L
BEL116027
66SLEFlares and Severe Flares , and Renal Flares
Derivation for rates of SFI flares
Within a treatment group, the unadjusted flare ( severe flare )rate per subject -year in a 
given phase will be calculated as:
Unadjusted flare (severe flare) r ate per subject -year =
total number of flares ( severe flares) in the phase / total number of y ears of follow -up 
time in the phase.
The calculation will not include baseline flares in the 116027 study .
Follow -up time derivation for ra tesof SFI flares
PhaseTreatment 
GroupDefinition
52-week 
Treatment 
PhaseTC, LTD (Week 52/Exit visit date – Day 0 date + 1)/ 365.25.
TH Phase TH (Week 24/T Xre-start date –Day 0 date + 1)/ 365.25.
RS Phase TH (Week 52/Exit visit –Week 24/TX re-start date )/ 365.25.
SELENA SLEDAI Organ System Domains
SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, 
laboratory tests, and physician’s assessment for each of 8 organ systems are given a weighted score and 
summed if present (marked ‘Yes’) at the time of the visit or in the preceding 10 days. The maximum 
theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 
‘No’), but in practice few subjects have scores > 45 [Buyon , 2005; Petri ,2005]. 
Organ system domain scores are the sum of the weights of items within the organ domain as defined in the 
table below .  
In this study, proteinuria is evaluated using spot -urine protein [represented as protein -creatinine ratio or PC 
Ratio (Add ref to 9.3.13) in the laboratory dataset] in lieu of the 24 -hour urine collection. PC ratio in mg/mg is 
considered equivalent to g/24 -hr urine prote in.
If the P/C ratio value is missing, then the value from the previous visit will be used. Specifically, the 
assessment for proteinuria indicated on the CRF will be used to calculate the SELENA SLEDAI score . 
In the eCRF, laboratory items on the SLEDAI m ay also be ticked ‘unknown’ to indicate the lab test was not 
available.  The laboratory items are: urinary casts, hematuria, proteinuria, pyuria, low complement, increased 
DNA binding, thrombocytopenia, and leukopenia.  Responses of ‘ Unknown ’ will be manag ed via LOCF 
  
List of organ systems, items, and weights for the assessments are provided. 2018N381035_00
CONFIDENTIA L
BEL116027
67Organ System Descriptor Weight
[1] CNS Seizure 8
Psychosis 8
Organic Brain Syndrome 8
Visual Disturbance 8
Cranial Nerve Disorder 8
Lupus Headache 8
CVA 8
[2] Vascular Vasculitis 8
[3] Musculoskeletal Arthritis 4
Myositis 4
[4] Renal Urinary Casts 4
Hematuria 4
Proteinuria 4
Pyuria 4
[5] Mucocutaneous Rash 2
Alopecia 2
Mucosal Ulcers 2
[6] Cardiovascular & Respiratory Pleurisy 2
Pericarditis 2
[7] Immunologic Low Complement 2
Increased DNA Binding 2
[8] Constitutional Fever 1
[9] Hematologic Thrombocytopenia 1
Leukopenia 1
PGA
The PGA is collected on a 10cm visual analogue scale (VAS).  
The standard scoring range for the P GA is 0 to 3, and the score will be rescaled for 
standard reporting b y multiply ing the collected score by  3/10 .  
During stud y conduct, it was noted that some sites erroneousl y received PGA scales 
that were 9.5cm in length due to a printing error , and some subjects utilized these 
scales before the error was discovered.  Per Notes to File (08Jan2015, and 
20Sep2017), an evaluation was performed and the decision was taken that this would 
result in minimal differences and not expected to affect an y outcomes, and therefore it 
was unnecessary  to adjust the anal ysis.
Prednisone Equivalent Conversion
Identification of Steroids
A concomitant medication is identified as a steroid if 
At least one associated ATC code (ATCCD1 –ATCCD6) begins with ‘H02.’  
AND
The ro ute meets the following criteria:
 Provides sy stemic exposure: oral, subcutaneous, intramuscular, intradermal, 
and intravenous.  
Although not s ystemic, intra-articular steroids are also identified for  2018N381035_00
CONFIDENTIA L
BEL116027
68prohibited medication rules.  
Topical routes of administration are excluded (e.g., topical, conjunctival, 
intranasal).  
Steroid doses will be converted to the prednisone -equivalent dose.
At data base release, all preferred terms identified with an ATC code beginning with 
‘H02’ will be reviewed to ensure a c onversion factor exists for all terms with a 
systemic or intra -articular route of administration. 
Similarly , all routes of administration for preferred terms with an ATC code 
beginning with ‘H02’will be reviewed to ensure all sy stemic or intra -articular r outes 
have been identified in the list above.  
In order to be converted, the frequency  and dose of the steroid must be present with 
the unit dose in milligrams (mg).
Reported dose for sy stemic steroid is converted to prednisone equivalent dose using 
conve rsion factor for each particular medication (refer to online calculator 
http://www.globalrph.com/corticocalc.htm).
Prednisone E quivalent Daily  Dose(mg) = Collected Dose(mg) x Conversion 
Factor x Frequency  Factor
Average Daily Dose Derivation
Average da ily prednisone dose at baseline is based on all days from the Screening 
visit date up t o and including the Day  0 visit date.
Post-baseline, average daily  prednisone dose is based on all day s between visits 
including the current visit date.
Average Dail y Do se (mg/day ) = Sum of Prednisone Equivalent Dail y Dose (mg) 
across all day s in the visit interval / Number of day s in the visit interval 2018N381035_00
CONFIDENTIA L
BEL116027
69Prednisone Conversion Factors (mg) 
Preferred termConversion factor for converting to a 
prednisone -equivalent dose
BETAMETHASONE 8.3333
BETAMETHASONE DIPROPIONATE 8.3333
BETAMETHASONE SODIUM PHOSPHATE 8.3333
BETROSPAM 8.3333
BUDESONIDE 0.3333
CELESTONA BIFAS 7.5
CORTISONE 0.2
CORTISONE ACETATE 0.2
CRONOLEVEL 8.3333
DEFLAZACORT 0.8333
DEPO -MEDROL MED LIDOKAIN 1.25
DEXAMETHASONE 6.6667
DEXAMETHASONE ACETATE 6.6667
DEXAMETHASONE SODIUM PHOSPHATE 6.6667
FLUOCORTOLONE 3
HYDROCORTISONE 0.25
HYDROCORTISONE ACETATE 0.25
HYDROCORTISONE SODIUM SUCCINATE 0.25
MEPREDNISONE 1.25
METHYLPREDNISOLONE 1.25
METHYLPREDN ISOLONE ACETATE 1.25
METHYLPREDNISOLONE SODIUM 
SUCCINATE1.25
PARAMETHASONE 2.5
PREDNISOLONE 1
PREDNISOLONE ACETATE 1
PREDNISOLONE SODIUM PHOSPHATE 1
PREDNISOLONE SODIUM SUCCINATE 1
PREDNISONE 1
PREDNISONE ACETATE 1
TRIAMCINOLONE 1.25
TRIAMCINOLO NE ACETATE 1.25
TRIAMCINOLONE ACETONIDE 1.25
Frequency Factors
Frequency Factor
BID 2
BIW 2/7
OAM 1/30
Once 1
PRN null
Q2H 12
Q2W 1/14
Q3H 8 2018N381035_00
CONFIDENTIA L
BEL116027
70Q3MO 1/84
Q3w 1/21
Q4H 6
Q4W 1/28
Q6H 4
Q8H 3
QAM 1
QD 1
QH 24
QHS 1
QID 4
QOD 1/2
QPM 1
QW 1/7
QWK 1/7
TID 3
TIW 3/7
UNK null
2 TIMES PER WEEK 2/7
3 TIMES PER WEEK 3/7
EVERY 2 WEEKS 1/14
EVERY 3 WEEKS 1/21
EVERY 4 Weeks 1/28
EVERY WEEK 1/7
13.6.4. Safety
Adverse Events
Adverse Events of Special Interest (AESI)
AESI will be defined per th e version of the PSAP/MedDRA in effect at the time of DBR.
Malignant Neoplasms
Malignancies Excluding non -melanoma skin cancer (NMSC)
Malignancies Including NMSC
Solid Tumour
Hematologic
Skin (All)
NMSC
Excluding NMSC
 Tumours of unspecified malignancy adju dicated a s malignant per GSK
Post- Infusion Systemic Reactions (PISR)
PISR per Anaphylactic Reaction Customized MedDRA Query (CMQ) narrow search
PISR per Anaphylactic Reaction CMQ broad search
PISR per Anaphylactic Reaction CMQ algorithmic search
Serious An aphylaxis per Sampson Criteria per GSK adjudication
Serious Acute PISR/Hypersensitivity Per GSK adjudication
Serious Acute PISR Excluding Hypersensitivity per GSK adjudication 2018N381035_00
CONFIDENTIA L
BEL116027
71Adverse Events
Adverse Events of Special Interest (AESI)
Serious Acute Hypersensitivity Reactions per GSK adjudication
Serious Delayed Ac ute Hypersensitivity Reactions per GSK adjudication
Serious Delayed Non -Acute Hypersensitivity Reactions per GSK adjudication
All Infections of Special Interest ( Opportunistic Infections (OI), Herpes Zoster (HZ), Tuberculosis 
(TB), And Sepsis; All and Seri ous, separately)
All opportunistic infections (OI) per GSK adjudication
OIper GSK adjudication excluding Tuberculosis and Herpes Zoster
Active Tuberculosis
Non-Opportunistic 
Opportunistic
Herpes Zoster
Non-Opportunistic 
Opportunistic
Recurrent 
Dissemin ated
Sepsis
Depression (including mood disorders and anxiety) /suicide/self -injury (All and Serious, separately)
Depression (including mood disorders and anxiety) (excluding suicide and self- injury)
Suicide/self -injury
Serous suicide/self -injury per GSK adj udication
Suicidal Behaviour
Completed Suicide
Suicidal Ideation
Self-injurious Behaviour without Suicidal Intent
Deaths
Laboratory Parameters
If a laboratory value which is expected to have a numeric value for summary purposes, has a 
non-detectable level reported in the database, where the numeric value is missing, but typically 
a character value starting with ‘<x’ or ‘>x’ (or indicated as less than x or greater than x in the 
comment field) is present, the number of significant digits in the observed va lues will be used 
to determine how much to add or subtract in order to impute the corresponding numeric value. 
oExample 1: 2 Significant Digits = ‘< x ‘ becomes x – 0.01
oExample 2: 1 Significant Digit   = ‘> x’ becomes x + 0.1
Example 3: 0 Significant Digi ts = ‘< x’ becomes x – 1    
13.6.5. Pharmacokinetic
Belimumab concentration
Assign zero to NQ values (Refer to GUI_51487 for further details) 2018N381035_00
CONFIDENTIA L
BEL116027
7213.6.6. Biomarker
13.6.6.1. Autoantibody , Complement, Immunoglobulins, and BLy S Protein
Biomarker Categorical Definitions
Anti-ds DNA
Positive: ≥ 30 IU /mL
Negative:  < 30 IU /mL
ANA
Positive: index ≥ 0.80
Negative: index < 0.80
aCL status
Positive:  if any of the three isotypes IgG, IgA or IgM are above the lower limit of quantification
Negative: if at least one isotype is non -missing and none of the isotypes are above the lower limit of 
quantification
Missing:  if all three isotypes are missing
BLyS Protein
Below LOQ: <0.02048 ng/mL 
Above LOQ: ≥0.02048 ng/mL 
C3
Positive: < 90 mg/dL
Negative: ≥ 90 mg/dL
Low: < 90 mg/dL
High: > 180 mg/dL
C4
Positive: < 10 mg/dL
Negative: ≥ 10 mg/dL
Low: < 10 mg/dL
High:  > 40 mg/dL
Immunoglobulin G
Low: < 6.94 g/L
Normal/High:  ≥ 6.94 g/L
Immunoglobulin A
Low: < 0.81 g/L 
Normal/High:  ≥ 0.81 g/L
Immunoglobulin M
 Low: < 0.48 g/L
 Norm al/high:  ≥ 0.48 g/L  
13.6.6.2. B-cell Subsets
Flow A ssays
B-cells can be assay ed using 3 different flow panels (identification of the flow panel 
responsible for each record is stored in BIMETHCD in the data transfer): Not all assays  2018N381035_00
CONFIDENTIA L
BEL116027
73will have the full list of B- cells assessed, but data relating to CD19 B -cells are collected 
using all 3 assay  methods, i.e. concentration of CD19 cells from the TBNK panel and 
CD19 event counts on the Plasma and Transitional panels (see detail in the table below). 
Because the number s of cells observed for the rare B -cell subsets are small, the 
concentration data cannot be adequately  summarised in the units provided in the 
SI/SDTM data. Therefore, these subsets are normalized and converted to an appropriate 
unit of measurement, i.e. c ount/mL . To normalize a rare B -cell subset and convert to 
count/mL , the CD19+ B -cell event count from the same flow panel as the B -cell subset 
being converted is used in the derivation.  For example, the CD19+ event count from the 
plasma flow panel is used to normalize B -cell subsets found in the plasma panel, whereas 
the CD19+ event count from the transitional panel is used when converting rare B -cell 
subsets from the transitional panel.  The stud y RAP should detail which rare B -cell 
subsets will be normal ized and converted. 
Source data
Below are the important variables included in a source data transfer for the B -cells to be 
reported in this study .
Flow PanelBiomarker 
testing 
method 
code Biomarker 
category 
code 
(BICATCD)1Analyte nameBiomarke r 
test code 
(BITESTCD)Units of 
Measurement 
(BIORRESU)
TBNK FLWTBNK CD19 CD19+ CONC GI/L
TBNK FLWTBNK CD19 CD19+ %LYMPH %
PLASMA FLWPLSM CD19 CD19+ EVENTS EVENTS
TRANSITIONAL FLWTRANS CD19 CD19+ EVENTS EVENTS
PLASMA FLWPLSM CD20 CD20+ CONC GI/L
PLASM A FLWPLSM CD20 CD20+ %CD19+ %
PLASMA FLWPLSM CD20 CD20+ EVENTS EVENTS
PLASMA FLWPLSM CDX136 Naïve CD20+ CD27 - CONC GI/L
PLASMA FLWPLSM CDX136 Naïve CD20+ CD27 - %CD19+ %
PLASMA FLWPLSM CDX136 Naïve CD20+ CD27 - EVENTS EVENTS
PLASMA FLWPLSM CDX137 Memory CD20+ CD27+ CONC GI/L
PLASMA FLWPLSM CDX137 Memory CD20+ CD27+ %CD19+ %
PLASMA FLWPLSM CDX137 Memory CD20+ CD27+ EVENTS EVENTS
PLASMA FLWPLSM CDX141 Activated CD20+ CD69+ CONC GI/L
PLASMA FLWPLSM CDX141 Activated CD20+ CD69+ %CD19+ %
PLASMA FLWPLSM CDX143 Plasma CD20 -CD138+ CONC GI/L
PLASMA FLWPLSM CDX143 Plasma CD20 -CD138+ %CD19+ %
PLASMA FLWPLSM CDX143 Plasma CD20 -CD138+ EVENTS EVENTS
PLASMA FLWPLSM CDX145 Plasmacytoid CD20+ CD138+ CONC GI/L
PLASMA FLWPLSM CDX145 Plasmacytoid CD20+ CD138+ %CD19+ %
PLASMA FLWPLSM CDX145 Plasmacytoid CD20+ CD138+ EVENTS EVENTS
PLASMA FLWPLSM CDX156 SLE Subset CD27+CD38+CD19+ CONC GI/L
PLASMA FLWPLSM CDX156 SLE Subset CD27+CD38+CD19+ %CD19+ %
PLASMA FLWPLSM CDX156 SLE Subset CD27+CD38+CD19+ EVENTS EVENTS
1Note: The SI data for Activated B -cells includes BICATCD=CDX141 for its concentration and %CD19 records, and 
CDX155 for its EVENTS record. For all other B -cell subsets, the BICATCD is the same for all 3 records. 2018N381035_00
CONFIDENTIA L
BEL116027
74B-cell unit conversions and Normalization of Rare B -cell Subsets
The Benly sta program standard is to report common B -cells (CD19, CD20, naïve, and 
memory ) in counts per microliter (uL). Common B -cells are not normalized but they  
must be converted to uL for reporting. To convert values reported from GI/L (= 109/L) to 
count per uL (= cells/mm3),multiply  the value b y 103or 1000.
Example: (0.25 GI/L) x (1000) = 250/uL  
Rare B -cell subsets are reported in counts per milliliter (mL). Rare B -cell subsets 
reported in GI/L will be converted to cells/ml u sing the following formula:
Normalized count/mL = (rare cell events) / (CD19+ events) * (CD19+ count/uL) * 1000
Note, the total B -cell ( CD19+ ) concentration from the TBNK panel should be converted 
to count /uLprior to the normalization and conversion of the Rare B- cell subset. 
Example: Normalization and conversion of Plasma CD20 -CD138+ to count/mL
Given:
Plasma CD20 -CD138+ number of event s= 16
CD19+ number of events on Plasma panel = 10250
CD19+ concentration on TBNK panel =  0.35 GI/L
Then:
Plasma CD2 0-CD138+ Normalized (count/mL) = 16 / 10250 * (0.35*1000) * 1000 = 546.34 count/mL
Reporting B cell subsets
The table below includes variables, labels and details of derivations used in the reporting 
of the B -cell subsets for this study .
B-cell subset label for displaysLab Test 
Code 
(LBTESTCD)Derivation for Normalization and / or Conversion 
of B-cell Subsets
Common B -cells
CD19 (/uL) CD19 May require conversion to /uL
CD20 (/uL) CD20 May require conversion to /uL
Naive CD19+CD20+CD27 -(/uL) CDX136 May require conversion to /uL
Naive CD19+CD20+CD27 -(%CD19) CDX13619 N/A
Memory CD19+CD20+CD27+ (/uL) CDX137 May require conversion to /uL
Memory CD19+CD20+CD27+ (%CD19) CDX13719 N/A
Rare B -cells
Activated CD19+CD20+CD69+ 
Normalized (COUNT/mL)CDX141N CDX155 EVENTS, CD19 EVENTS from Plasma 
Panel and CD19 concentration from TBNK Panel 2018N381035_00
CONFIDENTIA L
BEL116027
75Plasma CD19+CD20 -CD138+ 
Normalized (COUNT/mL)CDX143N CDX143 EVENTS, CD19 EVENTS from Plasma 
Panel and CD19 concentration from TBNK Panel
Plasmacytoid CD19+CD20+CD138+ 
Normalized (COUNT/mL)CDX145N CDX145 EVENTS, CD19 EVENTS from Plasma 
Panel and CD19 concentration from TBNK Panel
SLE Subset CD19+CD38b+CD27b+Lymph 
Normalized (COUNT/mL)CDX156N CDX156 EVENTS, CD19 EVENTS from Plasma 
Panel and CD19 concentration from TBNK Panel 2018N381035_00
CONFIDENTIA L
BEL116027
7613.7. Appendix 7: Reporting Standards for Missing Data
13.7.1. Premature Withdrawals
Element Reporting Detail
General Subject study  completion (i.e. as specified in the protocol) was defined as s
Treatm ent holiday  group: completion of the 24 -week treatment 
holiday  period plus the belimumab re -introduction treatment period 
to Week 52. 
Control and long-term discontinuation groups: completion of all 
visits to Week 52.
For reporting purposes, withdrawal from the maintenance phase is defined 
in Section 13.6.2 .
Withdrawn subjects were not replaced in the stud y
All available data from participants who were withdrawn from the study will be 
listed and all available planned data will be included in summary tables and 
figures, unless otherwi se specified.
Withdrawal visits will be slotted as per Appendix 3 : Assessment Windows or will 
be summarised as withdrawal visits.
13.7.2. Handling of Missing Data
Element Reporting Detail
General Missing data occurs when any requested data is not provided, leading to blank 
fields on the collection instrument:
oThese data will be indicated by the use of a “blank” in subject listing 
displays. Unless all data for a specific visit are missing in which case the 
data is excluded from the table. 
oAnswers such as “Not applicable” and “Not evaluable” are not considered 
to be missing data and should be displayed as such.
Outliers Any participants excluded from the summaries and/or statistical analyses will 
be documented along with the reason for exclu sion in the clinical study report.
LOCF In the LOCF dataset, missing values will be carried forward from the 
previous, non -missing available on-treatment assessment.
For the TH group, LOCF will not be applied across the TH and RS 
phases.
SLICC/ACR 
Damage IndexMissing data due to prohibited medication or study withdrawal will be 
imputed using LOCF
For the TH group, LOCF will not be applied across the TH and RS 
phases.
SELENA 
SLEDAI, Missing data will be imputed using LOCF.
For the TH group, LOCF will not be applied across the TH and RS 
phases. 2018N381035_00
CONFIDENTIA L
BEL116027
77Element Reporting Detail
Rebound, PGA If an individual SELENA SLEDAI item data is missing at the first 
timepoint in the RS phase, the item will be considered not present.   
Reduction in 
Daily  Prednisone 
DoseThe Dropout (DO)/Prohibited Med ication (PM)=Non -responder (NR) 
imputation will be applied.  If a subject withdraws from the study and/or 
receives a protocol- prohibited medication prior to a scheduled visit, the 
subject will be considered a non -responder (i.e. no reduction in 
prednisone) for that and subsequent visits.   
Average dail y 
prednisone doseObserved data will be used with no imputation .
Auto -antibodies, 
immunoglobulins, 
biomarkers, BLy S 
proteinObserved data will be used with no imputation
Immunogenicit y Observed data will be used with no imputation.
13.7.2.1. Handling of Missing and Partial Dates
Element Reporting Detail
General Partial dates will be displayed as captured in subject listing displays.
Adverse Events The eCRF allows for the possibility of partial dates (i.e., only month and year) to 
be recorded for AE start and end dates; that is, the day of the month may be 
missing. In such a case, the following conventions will be applied for calculating 
the time to onset and the duration of the event:
oMissing Start Day:First of the month will be used unless this is before the 
start date of study treatment ; in this case the Day 0 visit date (LTD and TH 
arms) or the study treatment start date (TC arm) will be used and hence the 
event is considered On -treatment as per Appendix 4 : Study Phases and 
Treatment Emergent Adverse Events .
oMissing Stop Day: Last day of the month will be used, unless this is after the 
stop date of study treatment ; in this case the study treatment stop date will 
be used.
Completely missing start or end dates will remain missing, with no imputation 
applied. Consequently, time to onset and duration of such events will be missing.
Concomitant 
Medications and 
Medical HistoryMedications with partial or missing start and/or stop dates will be a ssumed 
to be concomitant unless there is evidence through comparison of partial 
dates to suggest otherwise, for example if the day is missing, then the 
month and year will be compared to the month and year of the first dose 
date of study treatment and if t he month and year are the same or later, 
then the medication will be considered concomitant. 2018N381035_00
CONFIDENTIA L
BEL116027
7813.7.3. Handling of Prohibited Medications, Withdrawals and Deaths
Element Reporting Detail
Time to SFI 
FlaresEvaluated up to Week 52 
If a subject takes a prohibited medication during the time period being 
analyzed, the subject will be considered as having a SFI flare at the start 
date of the prohibited medication.   
If a subject withdraws from the study, the will be ce nsored at last flare
assessment date
If a subject dies, censor at the date of death
Time to Renal 
FlareEvaluated up to Week 52 
If a subject withdraws from the study, the will be censored at last renal  flare 
assessment date
If a subject dies, censor at the date of death
Number of SFI 
FlaresIf a su bject withdraws from the study, dies or takes a prohibited medication, 
the subject will be considered as having a SFI flare. 
Number of days 
of daily 
prednisone dose 
≥7.5 mg/day 
and/or 
increased by 
25%The Dropout (DO)/Prohibited Medication (PM)=Non -respo nder (NR) 
imputation will be applied.  If a subject withdraws from the study and/or 
receives a protocol- prohibited medication, the subject will be considered to 
have met this endpoint criteria (i.e, dose ≥ 7.5 mg/day and/or increased by 
25%) after the date of dropout or the date that the medication is started, 
whichever comes first, up until the visit date, and for those days in intervals 
for subsequent attended visits. Before this date, the evaluated endpoint will 
be assessed using available data.
Number of days 
of daily 
prednisone dose 
≤7.5 mg/day 
and/or 
decreased by 
25%The Dropout (DO)/Prohibited Medication (PM)=Non -responder (NR) 
imputation will be applied.  If a subject withdraws from the study and/or 
receives a protocol- prohibited medication, the subject will be considered a 
non-responder for this endpoint criteria (i.e., dose >7.5 mg/day and/or did 
not decreased by 25% ) after the date of dropout or the date that the 
medication is started, whichever comes first, and for those days in intervals 
for sub sequent attended visits. Before this date, the evaluated endpoint will 
be assessed using available data.
Reduction in 
Daily 
Prednisone 
DoseThe Dropout (DO)/Prohibited Medication (PM)=Non -responder (NR) 
imputation will be applied.  If a subject withdraws from the study and/or 
receives a protocol- prohibited medication prior to a scheduled visit, the 
subject will be considered a non -responder (i.e. no reduction in prednisone) 
for that and subsequent visits. 2018N381035_00
CONFIDENTIA L
BEL116027
7913.8. Appendix 8: Values of Potential Clinical Importanc e
13.8.1. Laboratory  Values
The following laboratory parameters are collected per the protocol.
Hematology Urinalysis Modified Chem -20
Total white blood cell count 
Differential:
Absolute Neutrophils
Segmented Neutrophils
Band Neutrophils
Myelocytes
Metamylocytes
Promyelocytes
Lymphocytes
Monocytes
Eosinophils
Basophils
Hemoglobin
Hematocrit
Red blood cell (RBC) count
Platelet count
Prothrombin time (PT)
Partial thromboplastin time (PTT)
  Protein
Glucose
Ketones
Occult blood
Microscopic e xamination 
including:
WBC per hpf
RBC per hpf
Dysmorphic RBC
Casts (specified by 
type e.g., RBC, WBC)
Spot Urine (protein : creatinine 
ratio)
Urine PregnancyElectrolytes:
Sodium
Potassium
Magnesium
Chloride
Carbon dioxide
Calcium adjusted for Al bumin
Inorganic Phosphate
Enzymes:
SGOT (AST)
SGPT (ALT)
Alkaline Phosphatase
Gamma glutanyl transpeptidase (GGT)
Lactic dehydrogenase (LDH)
Other:
Creatinine
Blood urea nitrogen (BUN)
BUN/creatinine ratio
Bilirubin, total
Protein, total
Albumin
Uric acid
Glucose
        Hepatitis B Viral DNA PCR
            Quantitative (HBV DNA)
Estimated Creatinine Clearance/ GFR 
(Cockroft -Gault)
Liver event follow- up assessments:
       Hepatitis A IgM antibody
       HBsAg and hep B Core antibody (IgM)
       Hepatitis C RNA
       Hepatitis delta antibody
       Cytomegalovirus IgM antibody
       Epstein -Barr viral capsid antigen IgM
            antibody
       Hepatitis E IgM antibody
       CPK
       Anti-smooth muscle antibody
       Type 1 anti -liver kidney microsomal
             antibodies
       PK
       IgG
       Fractionated bilirubin
       Serum acetaminophenBiological Markers
BLyS protein
Serum complement (C3 and C4) 
B-cell subtypes
Immunoglobulins
Serum immunoglobulin isotypes:  IgG, IgM, IgA
Immunogenicity
Autoantibodies
ANA
Anti-dsDNA
aCL 2018N381035_00
CONFIDENTIA L
BEL116027
8013.8.2. Adverse Event and Laboratory  Value Severity  Grade Tables
HEMATOLOGYGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Hemoglobin > 9.5 -11.0 g /dL > 8.0 –9.5 g/dL 6.5 -8.0 g/dL <6.5 g/dL
Leukocytes 3000 -3999/mm3 2000 -2999/mm3 1000 -1999/mm3 <1000/mm3
Absolute Neutrophil Count 1500 -1999/mm3 1000 -1499/mm3 500-999/mm3 <500/mm3
Platelets 75,000 -
99,999/mm350,000 –74,999/mm3 25,000 -49,999/ mm3 <25,000/mm3
Prothrombin Time (PT) >1.0-1.25 x ULN* >1.25-1.5 x ULN >1.5-3.0 x ULN >3.0 x ULN
Partial Thromboplastin Time (PTT) >1.0-1.66 x ULN >1.66-2.33 x ULN >2.33-3.0 x ULN >3.0 x ULN
Methemoglobin 5.0-10.0 % 10.1-15.0 % 15.1-20.0 % > 20%
(continued)
1. *ULN = Upper Limit of Normal                                                        Modified from DMID Adult Toxicity Tables, 2001 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
81Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
CARDIOVASCULARGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Cardiac Arrhythmia - Asymptomatic/transient; 
dysrhythmia; no treatment reqRecurrent/persistent 
dysrhythmia. Symptomatic; 
treatment reqUnstable dysrhythmia hospitalization
and tr eatment required
Hypotension Transient orthostatic 
hypotension, no treatmentSymptoms correctable 
with oral fluid treatmentIV fluid req,
no hospitalization reqHospitalization req
Hypertension Transient, increase
>20 mm/Hg; no treatmentRecurrent; ch ronic increase
>20 mm/Hg, treatment reqAcute treatment req; out patient 
hospitalization possibleHospitalization req
Pericarditis Minimal effusion Mild/moderate asymptomatic 
effusion, no treatmentSymptomatic effusion,
pain, ECG changesTamponade OR p ericardiocentesis 
OR surgery req
Hemorrhage, Blood Loss - Mildly symptomatic; 
no treatment requiredGross blood loss OR
1-2 units transfusedMassive blood loss OR
>2 units transfused
Modified from DMID Adult Toxicity Tables, 2001 (continued)
   
 
 2018N381035_00
CONFIDENTIA L
BEL116027
82Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
CHEMISTRIESGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Sodium
   Hyponatremia 130-135 meq/L 123-129 meq/L 116-122 meq/L <116 meq/L
   Hypern atremia 146-150 meq/L 151-157 meq/L 158-165 meq/L >165 meq/L
Potassium
   Hypokalemia 3.0-3.4 meq/L 2.5-2.9 meq/L 2.0-2.4 meq/L <2.0 meq/L
   Hyperkalemia 5.6-6.0 meq/L 6.1-6.5 meq/L 6.6-7.0 meq/L >7.0 meq/L
Phosphate
   Hypophosphatemia 2.0-2.4 mg /dL 1.5-1.9 mg/dL 1.0-1.4 mg/dL <1.0 mg/dL
Calcium -(Corrected For Albumin)
   Hypocalcemia 7.8-8.4 mg/dL 7.0-7.7 mg/dL 6.1-6.9 mg/dL <6.1 mg/dL
   Hypercalcemia 10.6-11.5 mg/dL 11.6-12.5 mg/dL 12.6-13.5 mg/dL >13.5 mg/dL
Magnesium
   Hypomagnesemia 1.2-1.4 meq/L 0.9-1.1 meq/L 0.6-0.8 meq/L <0.6 meq/L
Albumin
   Hypoalbuminemia 3.00-3.49 g/dL 2.50-2.99 g/dL 2.00-2.49 g/dL <2.00 g/dL
Bilirubin (Total)
   Hyperbilirubinemia (Total) >1.0-1.5 x ULN >1.5-2.5 x ULN >2.5-5 x ULN >5 x ULN
Glucose
   Hypoglycemia 55-64 mg/dL 40-54 mg/dL 30-39 mg/dL <30 mg/dL
   Hyperglycemia 116-160 mg/dL 161-250 mg/dL 251-500 mg/dL >500 mg/dL
   (nonfasting & no prior diabetes)
   Triglycerides 151-399 mg/dL 400-750 mg/dL 751-1200 mg/dL >1200 mg/dL
Creatinine >1.0-1.5 x ULN >1.5-3.0 x ULN >3.0-6.0 x ULN >6.0 x ULN
(continued)
Modified from DMID Adult Toxicity Tables, 2001 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
83Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
CHEMISTRIES (continued)GRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Uric Acid
   Hyperuricemia 7.5-10.0 mg/dL 10.1-12.0 mg/dL 12.1-15.0 mg/dL >15.0 mg/dL
Liver Transferases (AST, ALT, and 
GGT)1.25-2.5 x ULN >2.5-5.0 x ULN >5.0-10.0 x ULN >10.0 x ULN
Alkaline Phosphatase 1.25-2.5 x ULN >2.5-5.0 x ULN >5.0-10.0 x ULN >10.0 x ULN
Pancreatic Enzymes
Amylase >1.0-1.5 x ULN >1.5-2.0 x ULN >2.0-5.0 x ULN >5.0 x ULN
Pancreatic amylase >1.0-1.5 x ULN >1.5-2.0 x ULN >2.0-5.0 x ULN >5.0 x ULN
Lipase >1.0-1.5 x ULN >1.5-2.0 x ULN >2.0-5.0 x ULN >5.0 x ULN
Hypoglobulinemia (IgG)* 550-700 mg/dL 400-549 mg/dL 250-399 mg/dL <250 mg/dL
(continued)
1. *Eibl, 1995 ; Goldfa rb, 2001 ; Yamini , 2001 .                                                                                                                                       Modified from DMID Adult Toxicity Tables, 2001 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
84Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
GASTROINTESTINALGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Nausea Mild OR transient; 
reasonable intake 
maintainedMod discomfort 
OR intake decreased 
for <3 daysSevere discomfort OR 
minimal intake 
for 3 daysHospitalization required
Vomiting Mild OR transient; 
2-3 episodes/day OR 
mild vomiting lasting 
<1 weekMod OR persistent; 
4-5 episodes per day; 
OR vomiting lasting 
1 weekSevere vomiting of all 
foods/fluids in 24 hours 
OR o rthostatic hypotension
OR IV treatment reqHypotensive shock OR hospitalization 
required for IV treatment req
Diarrhea Mild or transient; 
3-4 loose stools per day 
OR mild diarrhea lasting 
<1 weekMod OR persistent; 
5-7 loose stools per day 
or diar rhea lasting 
1 weekBloody diarrhea; 
OR orthostatic hypotension 
OR >7 loose stools/day 
OR IV treatment reqHypotensive shock 
OR hospitalization req
Oral Discomfort/Dysphagia Mild discomfort, no difficulty 
swallowingDifficulty swallowing but able 
to eat and drinkUnable to swallow solids Unable to drink fluids; 
IV fluids req
Constipation Mild Moderate Severe Distention with vomiting
(continued)
Modified from DMID Adult Toxicity Tables, 2001 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
85Adverse Event and Laboratory  Value Severity  Grade Tabl es (continued)
RESPIRATORYGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Cough 
(for aerosol studies) Transient; no treatment Treatment associated 
cough; inhaled bronchodilatorUncontrolled cough; 
systemic treatm ent req
Bronchospasm Acute Transient; no treatment; 
FEV1 70 % to 
<80% 
(or peak flow)treatment req; normalizes with 
bronchodilator; 
FEV1 50 % to <70% 
(or peak flow)No Normalization 
with bronchodilator; 
FEV 25 % to <50% 
(or peak flow), retractio nsCyanosis; FEV1 <25% 
(or peak flow) OR intubated
Dyspnea Dyspnea on exertion Dyspnea with 
normal activityDyspnea at rest Dyspnea requiring O2 therapy 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
86Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
URINALYSISGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Proteinuria
Dispstick
Protein 1 + 2-3 + 4 + Nephrotic syndrome
Spot Urine:     
Protein:Creatinine 
Ratio mg/mg0.2-1.0 > 1.0 -2.0 > 2.0 -3.5 > 3.5
24 Hour Urine:
Protein200 mg -1g loss/day >1-2 g loss/day >2-3.5 g loss/day Nephrotic syndrome
OR >3.5 g loss/day
Hematuria Microscopic only
> 3 to < 10 RBC/hpfGross, No clots
10 RBC/hpfGross plus clots OR 
RBC castsObstructive OR transfusion required
(continued)
RBC = red blood cell; hpf = high power field.
Modified from DMID Adult Toxicity Tables, 2001
Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
MISCELLANEOUSGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREA TENING
Fever (oral >12 hours) 37.7-38.5C or
100.0 -101.5F38.6-39.5C OR
101.6 -102.9F39.6-40.5C OR
103-105 F>40.5C OR >105 F
Headache Mild; No treatment req Mod; or non -narcotic analgesia 
treatmentSevere; OR responds to initial 
narcotic treatm entIntractable; OR requiring 
repeated narcotic treatment
Allergic Reaction Pruritus without rash Localized urticaria Generalized urticaria 
angioedemaAnaphylaxis 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
87MISCELLANEOUSGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREA TENING
Cutaneous/Rash/ Dermatitis Erythema, pruritus rash 
OR dry desquamationDiffuse maculopa pular 
OR dry desquamationVesiculation OR moist 
desquamation ulcerationANY ONE: mucous membrane involvement, 
suspected 
Stevens- Johnson (TEN), erythema multiforme, 
necrosis req surgery, exfoliative dermatitis
Local Reaction (secondary 
to parenteral tr eatment- not 
vaccination or skin test)Erythema Induration <10 mm 
OR inflammation 
OR phlebitisInduration >10 mm 
OR ulcerationNecrosis of skin
Fatigue Normal activity 
Reduced <25%Normal activity 
Reduced 25 -50%Normal activity 
reduced > 50%; 
cannot workUnable to care for self
(continued)
Modified from DMID Adult Toxicity Tables, 2001 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
88Adverse Event and Laboratory  Value Severity  Grade Tables (continued)
NEUROLOGICGRADE 1 GRADE 2 GRADE 3 GRADE 4
MILD MODERATE SEVERE POTENTIALLY LIFE -THREATENING
Neuro -cerebellar Slight incoordination OR 
dysdiadochokinesiaIntention tremor OR 
dysmetria OR slurred speech 
OR nystagmusAtaxia requiring assistance to walk 
or arm incoordination interfering 
with ADLsUnable to stand
Neuro -psych/ moo d none Severe mood changes requires 
medical interventionAcute psychosis requiring 
hospitalization
Paresthesia 
(burning, tingling, etc)Mild discomfort; 
no treatment neededMod discomfort 
non-narcotic analgesia reqSevere discomfort; OR narcotic 
analgesia req with symptomatic 
improvementIncapacitating; OR not responsive 
to narcotic analgesia
Neuro -motor Mild weakness in muscle 
of feet but 
able to walk and/or mild 
increase or decrease in 
reflexesMod weakness in feet (unable to walk on 
heels and/ or toes), mild weakness in 
hands, still able to do most hand tasks 
and/or loss of previously present reflex 
or development of hyperreflexia 
and/or unable to do deep knee 
bends due to weaknessMarked distal weakness (unable to 
dorsiflex toes or foot drop ), and 
mod proximal weakness ie, in 
hands interfering with ADLs and/or 
requiring assistance to walk and/or 
unable to rise from chair 
unassistedConfined to bed or wheelchair 
because of muscle weakness
Neuro -sensory Mild impairment 
sensations, 
(ie, vibra tory, pinprick, 
hot/cold in great toes) in 
focal area or symmetrical 
distributionMod impairment mod de -sensation, 
(ie, of vibratory, pinprick, hot/cold to 
ankles) and/or joint position or mild 
impairment that is not symmetrical.Severe impairment (dec or loss of 
sensation to knees or wrists) or 
loss of sensation of at least mod 
degree in multiple different body 
areas (ie, upper and lower 
extremities)Sensory loss involves limbs 
and trunk
(concluded)
Modified from DMID Adult Toxicity Tables, 20 01 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
8913.9. Appendix 9: Adverse Events of Special Interest
The primary  source for rules governing identification, adjudication, and reporting of 
Adverse Events of Special I nterest is the Program Safety  Anal ysis Plan (PSAP).  AESI  
are defined using preferred terms from the current version of MedDRA.  The intent is to 
update these definitions semi- annuall y using the newest MedDRA version.  Preferred 
terms used in the current and prior versions of MedDRA can be found in IMMS at the 
following path /Study  File/GSK1550188/_Project/Meta Anal ysis/PSAP/AESI _201.csv.
13.9.1. Malignant n eoplasms
Malignant neoplasms are identified using the sub-SMQs of Malignant or unspecified 
tumours (20000091) , malignancy related conditions (20000092) , haematological 
malignant tumours (20000227), no n-haematological malignant tumours (20000228), 
haematological tumours of unspecified malignancy  (20000229) and non -haematological 
tumours of unspecified malignancy  (20000230) under the current version of MedDRA.  
The sub- SMQ of Malignant or unspecified tum ours contains two further subcategories: 
“Malignant Tumours” and “ Tumours of unspecified malignancy .”  Tumours of 
unspecified malignancy  will be reviewed b y GSK and identified as malignant or non -
malignant for reporting.
Malignancies other than those in th e “Tumours of unspecified malignancy ” category  will 
be categorized as hematologic, skin, or solid, based on a CMQ developed by the MAH.  
In addition, the following customizations have been made since MedDRA v19.1:
The term “Paraneoplastic glomerulonephriti s” has been removed from the SMQ as it 
is a complication of malignancy . 
The term “Mismatch repair cancer s yndrome” has been added as a tumour of 
unspecified malignancy
The term “Malignant meningioma metastatic” has been added as a solid tumor ty pe.
The te rm “Marginal zone ly mphoma recurrent” has been added as a hematological 
tumor ty pe.
The term “Skin neoplasm bleeding” has been added as a tumour of unspecified 
malignancy .
The term “Astroblastoma” has been added as a solid tumour ty pe.
The term “Epstein Ba rr virus positive mucocutaneous ulcer” has been added as a 
hematological tumour type.
The term “Langerhans cell sarcoma” has been added as a solid tumour ty pe.
The term “Naevoid melanoma” has been added as a skin tumour ty pe.
The term “Nasophary ngeal cance r metastatic” has been added as a solid tumour ty pe.
The term “Phospaturic mesench ymal tumour” has been added as a solid tumour ty pe.
The term “Primary  gastrointestinal follicular ly mphoma” has been added as a 
hematological tumour type. 2018N381035_00
CONFIDENTIA L
BEL116027
90The term “Squamous cell breast carcinoma” has been added as a solid tumour ty pe.
The term “Transformation to acute m yeloid leukaemia” has been added as a 
hematological tumour type.
The term “FIP1L1/PDGFR alpha fusion kinase positive” has been added as a 
hematological tumour type.
The term “Gleason grading score” has been added as a solid tumour ty pe.
The term “Oncot ype test” has been added as a solid tumour ty pe.
The term “Intestinal metastasis” has been added as an unspecified tumour type.
The term “Maternal cancer in pregna ncy” has been added as an unspecified tumour 
type.
The term “ Microsatellite instability  cancer” has been added as an unspecified tumour 
type.
The term “ Pulmonary  tumour thrombotic microangiopathy ” has been added as an 
unspecified tumour t ype.
The term “ Tum our cavitation ” has been added as an unspecified tumour t ype.
The term “ Malignant urinary  tract obstruction” has been added as a solid tumour ty pe.
Non-melanoma skin cancer (NMSC) will be categorized using a CMQ developed by  the 
Marketing authorization h older (MAH) 
Note beginning with MedDRA v20.0 in 2017, there will be two new sub -SMQs of 
Hematological Malignancies. These do not result in any  changes to how malignant 
neoplasms are identified.
13.9.2. Post -infusion systemic reactions
Post-infusion systemic reac tions will be identified using a customization of the 
Anaph ylactic Reaction SMQ ( 20000021 ). This SMQ includes a broad list of preferred 
terms including s ymptoms of sy stemic injection/infusion reactions and hy persensitivity  
reactions and anaph ylaxis. For th e Anaphy lactic Reaction query , 4 categories of preferred 
terms are considered, including a set of core anaphy lactic terms (Category  A), upper 
airway/respiratory  terms (Category  B), angioedema/urticaria/pruritus/flush terms 
(Category  C), and cardiovascular/ hypotension terms (Category  D).
The customizations of the SMQ involve terms in Categories A, B and C. Category  A has 
been modified to include the following additional terms: “ Infusion -related reaction”,
“Drug h ypersensitivity ”, “Hypersensitivity ”, and “Urt icarial vasculitis” .Category  B has 
been modified to include the following additional terms: “Orophary ngeal oedema” and 
“Phary ngeal oedema”.  Category  C has been modified to include the following additional 
term: “Fixed eruption”.  GSK has also removed threeterms that are not relevant for an 
analysis of hy persensitivity  reactions to belimumab (“Anaph ylactic transfusion reaction” , 
“Dialysis membrane reaction”, and “First use s yndrome”). Anaphy lactic transfusion 
reaction is an adverse event associated with a blood transfusion, not related to study   2018N381035_00
CONFIDENTIA L
BEL116027
91medication.  First use s yndrome and dial ysis membrane reaction are associated with 
adverse events related to kidney  transplants and dialy sis, not related to study  medication.
Algorithmic Search Criteria
The post-infusion systemic reactions per Anaph ylactic Reaction SMQ algorithmic search 
are defined as follows:
Subjects must have the following associated with the same infusion/injection: 
a.at least 1 AE coding to a Category  A preferred term or
b.2 AEs, 1 coding to a Category  B preferred term and the other coding to a Category  C 
preferred term or
c.2 AEs, 1 coding to a Category  D preferred term and the other coding to either a 
Category  B preferred term or to a Category  C preferred term.
For the algorithmic search, if any event at a given infusion/injection meets the definition 
under criteria a, b or c, then all events in Categories A, B, C and D associated with that 
injection/infusion will be considered AESI .
For CSR reporting, all post-infusion systemic reaction AESI s defined via narrow, broad, 
or algorithmic search, the AEs need to have occurred on the day  of an infusion/ injection 
or within 3 days after an infusion/ injection. See Section 13.3.4for the definition of the 3 -
day assessment window.  GSK will review all serious events identified via the broad 
search occurring within 21 day s after an infusion/ injection, and adjudicate these events as 
post-infusion systemic reactions or h ypersensitivity reactions per the criteria in Section
13.9.10.2 .  Adverse events with partial or missing start dates will be included unless there 
is evidence through comparison of partial dates to suggest otherwise.
Sampson Criteria
Sampson et al define anaphy laxis as a s evere, potentially  fatal, s ystemic allergic reaction 
that occurs suddenl y after contact with an allergy -causing substance. In addition, one of 
the following 3 criteria must be met: (1) acute onset of illness with involvement of skin or 
mucosal tissue, acco mpanied with either respiratory  compromise, reduced blood pressure, 
or hy potension -related symptoms of end -organ d ysfunction (2) reduced blood pressure 
associated with a known allergen or (3) two or more of the following that occur rapidly  
after exposure to an allergen: a) involvement of skin -mucosal tissue b) respiratory  
compromise c) reduced blood pressure d) persistent GI  symptoms. 
With the exception of GI sy mptoms, all sy mptoms required to assess anaphy laxis per 
Sampson criteria would be identified b yBroad Anaphy laxis SMQ or the Anaphy lactic 
Reaction SMQ algorithmic. Therefore, an y events falling under the below criteria will be 
adjudicated b y GSK prior to database release to determine if serious anaphylaxis per 
Sampson criteria is met.
Possible cases of serious anaph ylaxis per Sampson criteria will be identified as follows:
a.Any Infusion/ Injection -related Reaction per Anaphy lactic Reaction SMQ broad  2018N381035_00
CONFIDENTIA L
BEL116027
92search SAE which occurs on the day  of an injection.
b.Any AE or SAE in the “Gastrointestinal disorders” SO C that occurs on the day  that 
criterion in a) above is met.
c.Any anaphy laxis and hy persensitivity  reactions per Anaph ylactic Reaction SMQ 
algorithmic search SAE which occurs on the day  of an infusion/ injection.
13.9.3. Infections
The infections of special interest are described below.
13.9.3.1. Opportunistic Infections
Opportunistic infections will be identified using a broad CMQ developed by  the MAH .
Any events falling under these preferred terms will be adjudicated b y GSK prior to 
database rel ease to determine if criteria a remet for an opportunistic infection, per the 
criteria in Section 13.9.10.3 .  
13.9.4. Mycobacterium Tuberculosis
Tuberculosis events will be identified using a CMQ developed b y the MAH . Any  events 
falling under these preferred terms will be adjudicated by  GSK prior to database rel ease 
to determine if criteria are met for an opportunistic infection (Section 13.9.10.3 ).  
13.9.5. Herpes Zoster
Herpes Zoster events will be identified u sing a CMQ developed b y the MAH.  Additional 
manual adjudication b y GSK prior to database release will identify  events that are 
recurrent or disseminated (Section 13.9.10.3 ).
13.9.6. Pneumonia
Pneumonia events will be i dentified using a CMQ developed b y the MAH.  Pneumonia 
events will not be reported separately , but are being flagged in the event further 
evaluation is necessary .
13.9.7. Sepsis
Sepsis events will be identified using a CMQ developed b y the MAH.
13.9.8. Depression/suicide/ self-injury
13.9.8.1. Depression (excluding suicide and self -injury )
Depression events will be identified using a CMQ including the preferred terms from the 
depression (excluding suicide and self injury ) SMQ ( 20000035 ) plus additional terms 
added b y the MAH. 2018N381035_00
CONFIDENTIA L
BEL116027
9313.9.8.2. Suicide and Self -Injury
Suicide and self -injury events will be identified using the SMQ ( 20000035 ) preferred 
terms .
13.9.9. Fatalities
All fatalities will be identified in the clinical database and subsequently  adjudicated by 
the GSK SRT into a general category  of death (Section 13.9.10.5 ).
Post-study  fatalities that are captured in ARGUS prior to CSR approval, but are not 
captured in the clinical database, will be described within the CSR text but cannot be 
included in statist ical post -text display s. 
13.9.10. GSK SRT A djudication of A dverse Events of Special Interest
Adverse events of special interest (AESI) are identified per the preferred terms and other 
criteria described in Section 13.9.  The following AESI  are adjudicated at the subject 
level by  the GSK SRT during regular SRT meetings or during quarterly  adjudication.  
The adjudication occurs prior to database release and is performed for reporting purposes, 
per the criteria described below.
Assignment of adjudication flags in th e clinical database will occur as part of the 
quarterl y SRT review process.  In addition, as part of individual study  close -out 
procedures, the adjudications should be finalized as follows:
Just preceding data base release ( DBR ), allow ing time to send queries or update the 
eCRF/database as necessary  prior to DBR.
After DBR to provide final confirmation of adjudications and ensure there are no new 
AESI  or relevant data changes to adjudicated events since the pre-DBR adjudication.  
This would be a requirement for declaring data a freeze (DBF).
13.9.10.1. Malignancies
All malignancies identified via the preferred terms will be reviewed b y GSK SRT.  The 
classification of malignancies as solid tumor, hematological, and skin will be reviewed 
against the verbatim term to confirm an appropriate and accurate preferred term has been 
assigned, or to recommend follow -up with the investigator for additional specificit y on 
the verbatim term. In addition, malignancies that are flagged more th an once, e.g., based 
on a term for both a diagnostic procedure and a diagnosis, will be adjudicated as one 
event.
Tumors of unspecified malignancy , as identified via preferred terms, will be reviewed 
clinically  by the GSK SRT for reporting.  In general, n on-serious events in the tumours of 
unspecified malignancy  with insufficient information will be categorized as not 
malignant. Serious adverse events with insufficient information will be categorized as 
either not malignant or malignant based on the t ype oftumor and likelihood the tumor 
type is malignant ( e.g., thy roid nodules are common in SL E patients and are generall y not  2018N381035_00
CONFIDENTIA L
BEL116027
94malignant; tumor ty pes with higher likelihood for malignancy  would be assumed to be 
malignant ).
13.9.10.2. Serious h ypersensitivity and post -infusion systemic reactions
Before the data base is released, GSK SRT will review all serious cases identified from 
the Broad Anaph ylaxis SMQ as described in Section 13.9, apply ing clinical judgment to 
determine if the preferred terms are indicative of a hy persensitivity  or infusion/injection
reaction. Time to onset after an infusion/injection and details provided in the clinical 
narratives with respect to the nature and likel y cause of the events are taken into 
consideration. Time to onset within 24 hours is generall y applied to post 
infusion/injection reactions. The GSK SRT adjudicates serious h ypersensitivity  reactions 
into a category  based primarily  on time to onset: acute ( onset ≤ 1 day ), delay ed acute 
(onset 2- 3 day s), or delayed, non- acute ( onset 4- 21 day s).  In addition to time to onset, 
description of associated sy mptoms is taken into account for this categorization. 
In addition, p ossible cases of serious anaph ylaxis pe r Sampson criteria will be identified 
per the criteria in Section 13.9.Any events falling under these criteria will be adjudicated 
by GSK prior to database release to determine if serious anaphy laxis per Sampson criteria 
is met.
13.9.10.3. Potential opportunistic i nfections
Opportunistic infections (OIs) will be identified using a list of preferred terms , designed 
to cast a wide net for events potentially  indicative of an opportunistic infection . Any  
identified events will be adjudicated b y the GSK SRT prior to database release to 
determine if criteria are met for an opportunistic infection. Targeted follow -up is sought 
for events with insufficient information. I n general, potential OI s that are non -serious 
with insufficien t information to adjudicate will be considered non -opportunistic. Potential 
OI SAEs with insufficient information to adjudicate will be considered opportunistic. See 
below for a list of agreed upon pathogens and infections considered to be opportunistic
for the purpose of adjudication.
Pathogens and Infections Considered Opportunistic :
Acinetobacter infection
Aspergillosis
Blastomy cosis, extrapulmonary
Candidiasis of esophagus, bronchi, trachea or lungs
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis infection, chronic intestinal (greater than 1 month duration)
CMV disease other than liver, spleen, or nodes
Herpes simplex – bronchitis, pneumonitis, or esophagitis
Herpes Zoster (adjudication details are belo w)
Histoplasmosis disseminated or extrapulmonary
Human poly omavirus infection
Isosporiasis, chronic intestinal (greater than one month duration) 2018N381035_00
CONFIDENTIA L
BEL116027
95Listeriosis
Mycobacterium avium complex or M. Kansasii, disseminated or extrapulmonary
Nocardiosis
Other non-tuberculous mycobacterium (NTM) infections (other species or 
unidentified species), disseminated or extrapulmonary *
Polyomavirus (JC virus or BK virus) associated nephropathy  (including PML)
Pneumocy stis jiroveci infection
Toxoplasmosis of brain
* Extra pul monary  NTM infections are generall y considered an OI unless the affected 
extra pulmonary  area followed a wound or trauma.
In addition, GSK SRT will review all SAEs, including those coded under preferred terms 
not in the preferred term definition , and utili zing the supplemental/narrative information, 
will adjudicate the SAEs as OI if warranted based on medical judgment. 
Other Infections of Interest but not generally considered opportunistic:
Mycobacterium tuberculosis (adjudication details are below)
Herpe s Zoster
Herpes Zoster events will be identified per preferred terms . Adjudication by  GSK SRT 
will identify  events that are recurrent or disseminated. Herpes Zoster is considered 
disseminated if there is involvement of other organs other than the skin or if skin lesions 
(1) cross the midline of the body  or (2) are in non -adjacent dermatomes or (3) are located 
in more than three adjacent dermatomes.  Herpes zoster is considered an opportunistic 
infection if it is adjudicated as recurrent or disseminated.  H owever, there may  be some 
uncommon occurrences of a herpes zoster case that is adjudicated as an OI but is neither 
recurrent or disseminated.
Mycobacterium T uberculosis
Tuberculosis ( TB)cases a re reviewed by the GSK SRT to determine if a case is an OI. 
The following principles are applied: Pulmonary TB in an endemic area is not considered 
an OI. Pulmonary  TB in a non-endemic area would be considered an OI unless the 
subject had close contact with a person infected with TB. Extra pulmonary  TB is 
generall y considered an OI unless the affected extra pulmonary  area followed a wound or 
trauma. 2018N381035_00
CONFIDENTIA L
BEL116027
9613.9.10.4. Suicide/self -injury
Suicide and self -injury  SAE s will be identified using the preferred terms and 
subsequently  adjudicated into the following categories:
Adjudicated Category
Suicidal Behaviour
      Completed Suicide
Suicidal I deation
Self-Injurious Behaviour without Suicidal I ntent
In addition, GSK SRT will review all SAEs, including those coded under preferred terms 
not in the definition, and utilizing the suppleme ntal/narrative information, will adjudicate 
the SAEs as suicide/self -injury  if warranted based on medical judgment. 
13.9.10.5. Fatalities
All fatalities will be identified in the clinical database and subsequently  adjudicated by 
the GSK SRT into a general category  of death.
All fatalities will be adjudicated into one of the following categories:
Adjudicated Category of Death
SLE-Related
Infectious
Vascular
Gastrointestinal
Respiratory
Malignancy
Hypersensitivity
Suicide
Surgical Complication
Unknown
Hematologic
Trauma
Additional ‘categories of death’ may  be added in the future should a fatality  not clearl y 
fit into one of the ‘categories’ listed above.  The ‘categories’ will not change unless 
agreed upon b y the GSK SRT .   2018N381035_00
CONFIDENTIA L
BEL116027
9713.10. Appendix 10: Abbreviations & Tra de Marks
13.10.1. Abbrev iations
Abbreviation Description
ADaM Analysis Data Model
aCL Anti-cardiolipin Antibody
ACR American College of Rheumatology
AE Adverse Event
AESI AEs of Special Interest
Anti-dsDNA Anti-double -stranded DNA
ANA Anti-nuclear Antibody
ATC Anatomical Therapeutic Chemical
BMI Body mass index
BUN Blood urea nitrogen
CDISC Clinical Data Interchange Standards Consortium
C3 / C4 Complement 3 / Complement 4
CI Confidence Interval
CNS Central Nervous System
CRF Case Report Form
CS Clinical Statistics
CSR Clinical Study Report
eCRF Electronic Case Report Form
DO Dropout
DOB Date of Birth
DP Decimal Places
DQE Data Quality Evaluation Report
eCRF Electronic Case Report Form
GFR Glomerular Filtration R ate
GSK GlaxoSmithKline
GUI Guidance
hpf High-power Field
ICH International Conference on Harmonisation
IDSL Integrated Data Standards Library
IgA, G, M Immunoglobulin A, G, M
IM Intramuscular
IMMS International Modules Management System
ITT Intention -to-treat
IV Intravenous
LLN Lower Limit of Normal
LOCF Last Observation Carried Forward
LOQ Limit of Quantification
LTD Long -term discontinuation
MedDRA Medical Dictionary for Regulatory Activities
MHE Mental Health Enhanced Score
NMSC Non-melanoma skin cancer
NR Non-respon der
OI Opportunistic Infections
PCI Potential Clinical Importance 
PD Pharmacodynamic 2018N381035_00
CONFIDENTIA L
BEL116027
98Abbreviation Description
PDMP Protocol Deviation Management Plan
PGA Physician’s Global Disease Assessment
PK Pharmacokinetic
PM Prohibited medication
PopPK Population Pharmacokinetic 
PSAP Program Safety Analysis Plan
PT Preferred Term/Prothrombin Time
PTT Partial thromboplastin Time
QC Quality Control
RAP Reporting and Analysis Plan
RAMOS Randomization & Medication Ordering System
RBC Red blood cell
RS Re-start Phase
SAC Statist ical Analysis Complete
SAE Serious Adverse Event
SC Subcutaneous
SD Standard deviation
SDTM Study Data Tabulation Model
SE Standard error
SELENA Safety of Estrogen in Lupus National Assessment
SI System independent
SFI SLE Flare Index
SLE Systemic Lupus Erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLICC Systemic Lupus International Collaborating Clinics
SMQ Standardized MedDRA Query
SoC Standard of Care
SOC System Organ Class
SOP Standard Operation Procedure
SS SELENA SLEDAI 
TC Treatment Control
TH Treatment Holiday
TLFs Tables, Listings, and Figures
TX Treatment
ULN Upper Limit of Normal
uPCR Urine Protein: Creatinine R atio.
VAS Visual Analogue Scale
WOCF Worst Observation Carried Forward
13.10.2. Trademarks
Trademarks of the GlaxoSmithKline 
Group of CompaniesTrademarks not owned by the 
GlaxoSmithKline Group of Companies
BENLYSTA SAS
BLyS 2018N381035_00
CONFIDENTIA L
BEL116027
9913.11. Appendix 11: List of Data Display s
13.11.1. Data Display  Numbering
The following numbering will be applied for RAP generated display s:
Section Tables Figures
Study Population 1.1 to 1. 17 1.1 to 1. 1
Efficacy 2.1 to 2.12 2.1 to 2.3
Safety 3.1 to 3.52 3.1 to 3.6
Pharmacokinetic 4.1 to 4.1 4.1 to 4.2
Biomarker 5.1 to 5. 23 5.1 to 5. 10
Section Listings
ICH Listings 1 to 39
Other Listings 40to 51
13.11.2. Deliverables
Priority Description
H Included in Headline Data Package 2018N381035_00
CONFIDENTIA L
BEL116027
10013.11.3. Study Population Tables
Study Population Tables
No. Population Title Programming NotesPriority
Headline Results 
denoted by H
Subject Disposition
1.1. ITT Subject Enrollment
1.2. ITT Enrolment by Country and Site EudraCT/Clinical Operations
1.3. Screened Study Populations IDSL
1.4. Screened Screening Status and Reasons for Failing Screening Journal Requirements
1.5. ITTSubject Disposition for the Subject Conclusio n Record (52 -
Week Treatment Phase)ICH E3, FDAAA, EudraCT
1.6. ITTSubject Disposition for the Subject Conclusion Record 
(Maintenance Phase)ICH E3, FDAAA, EudraCT
1.7. ITT Time to Withdrawal from the Study Benlysta Standard
1.8. ITT Subject Disposition at Each Study Epoch ICH E3
Protocol Deviation
1.9. ITT Subjects with Important Protocol Deviations ICH E3
Demographic and Baseline Characteristics
1.10. ITT Demographic and Baseline Characteristics ICH E3, FDAAA, EudraCT H
1.11. ITT Age Ranges EudraCT
1.12. ITT Race and Rac ial Combination Details ICH E3, FDA, FDAAA, EudraCT
Current and Prior Medical History
1.13. ITT General Medical HistoryICH E3  
 
 2018N381035_00
CONFIDENTIA L
BEL116027
101Study Population Tables
No. Population Title Programming NotesPriority
Headline Results 
denoted by H
Baseline Disease Activity and SLE Medication Use
1.14. ITT Baseline Disease Activity Benlysta Standard H
1.15. ITT SELENA SLEDAI Organ and Item Involvement at Baseline Benlysta Standard H
1.16. ITT Allowable SLE Medication Usage at Baseline Benlysta Standard
1.17. ITT Steroid, Anti -malarial and Immunosuppressant Use at Baseline Benlysta Standard
13.11.4. Study Population Figures
Study Population : Fig ure
No. Population Title Programming Notes Priority
Time to Withdrawal
1.1 ITT Time to Withdrawal Study Population H 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
10213.11.5. Efficacy  Tables
Efficacy: Tables
No. Population Title Programming NotesPriority
Headline Results 
denoted by H
Flares
2.1. ITT Time to First SFI Flare to Week 52 Primary endpoint H
2.2. ITT SFI Flares per Subject -year from Day 0 to Week 52 Secondary endpoint
2.3. ITT Time to First SFI Severe Flare to Week 52 Secondary endpoint H
2.4. ITT Time to First Renal Flare to Week 52 Exploratory endp oint H
2.5. ITTTime to First Renal Flare to Week 52 [1] Among Subjects with 
Baseline Proteinuria >0.5g/24hr EquivalentExploratory endpoint
Rebound and SELENA -SLEDAI
2.6. ITTSELENA SLEDAI Rebound (LOCF) (52-Week Treatment 
Phase)Secondary endpoint H
2.7. ITTSELENA SLEDAI Change from Baseline (LOCF) (52-Week 
Treatment Phase)Secondary endpoint
PGA
2.8. ITT PGA Change from Baseline (52- Week Treatment Phase) Other/exploratory endpoint
Prednisone
2.9. ITTNumber of Days of Daily Prednisone Dose >=7.5 mg/day 
and/or In creased by 25%Secondary endpoint
2.10. ITTNumber of Days of Daily Prednisone Dose <=7.5 mg/day 
and/or Decreased by 25%Secondary endpoint 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
103Efficacy: Tables
No. Population Title Programming NotesPriority
Headline Results 
denoted by H
2.11. ITTPrednisone Percent Change from Baseline (52 -Week 
Treatment Phase)Other/exploratory endpoint
2.12. ITTPrednisone R educed to <= 7.5 mg/day by Visit (DO/TF=NR) 
among Subjects with Baseline Prednisone Dose > 7.5 mg/day 
(52-Week Treatment Phase)Other/exploratory endpoint
13.11.6. Efficacy  Figures
Efficacy: Figures
No. Population Title Programming Notes Priority
Flares
2.1. ITT Time to First SFI Flare to Week 52 Primary endpoint H
2.2. ITT Time to First Severe SFI Flare to Week 52 Secondary endpoint H
Rebound and SELENA -SLEDAI
2.3. ITTSELENA SLEDAI Change from Baseline by Visit (LOCF) 
(52-Week Treatment Phase)Secondary endpoint 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
10413.11.7. Safety Tables
Safety : Tables
No. Population Title Programming NotesPriority
Headline Results
Denoted by H
Concomitant Medications
3.1. ITTConcomitant Medications by ATC Level 1 and ATC Level 4 
Term for the 52 -Week Treatment PhaseICH E3
Study AgentExposure
3.2. ITT Study Agent Exposure (52 -Week Treatment Phase) ICH E3
SLICC
3.3. ITTSLICC/ACR Damage Index Change from Baseline (52 -
Week Treatment Phase)Other/exploratory endpoint
Adverse Events
3.4. ITT Adverse Events (52 -Week Treatment Phase)Benlysta standardH
3.5. ITT Adverse Events by SOC (52- Week Treatment Phase)Benlysta standard
3.6. ITTSerious Adverse Events by SOC (52 -Week Treatment 
Phase)Benlysta standard
3.7. ITTStudy Agent Related Adverse Events by SOC (52- Week 
Treatment Phase)Benlysta stand ard
3.8. ITTAdverse Events Resulting in Study Agent Discontinuation 
by SOC (52 -Week Treatment Phase)Benlysta standard 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
105Safety : Tables
No. Population Title Programming NotesPriority
Headline Results
Denoted by H
3.9. ITTAdverse Events by SOC and PT (52-Week Treatment 
Phase)ICH E3H
3.10. ITTSerious Adverse Events by SOC and PT (52 -Week Treatment 
Phase)Benlysta Standard H
3.11. ITTStudy Agent Related Adverse Events by SOC and PT (52 -Week 
Treatment Phase)ICH E3
3.12. ITTAdverse Events Resulting in Study Agent Discontinuation by 
SOC and PT (52- Week Treatment Phase)IDSLH
3.13. ITT Adverse Events by PT (52 -Week Treatment Phase) Benlysta Standard
3.14. ITT Serious Adverse Events by PT (52 -Week Treatment Phase) Benlysta Standard
3.15. ITTStudy Agent Related Adverse Events by PT (52 -Week 
Treatment Phase)Benlysta Standard
3.16. ITTAdverse Events Resulting in Study Age nt Discontinuation by PT 
(52-Week Treatment Phase)Benlysta Standard
3.17. ITTCommon (>5%) Non -Serious Adverse Events by SOC and PT 
(52-Week Treatment Phase)
(Number of Subjects and Occurrences)FDAAA, EudraCT
3.18. ITTSerious Adverse Events by SOC and PT (52 -Week 
Treatment Phase) (Number of Participants and 
Occurrences)FDAAA, EudraCTH
3.19. ITTAdverse Events by SOC and PT and Maximum Severity (52 -
Week Treatment Phase)IDSL 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
106Safety : Tables
No. Population Title Programming NotesPriority
Headline Results
Denoted by H
3.20. ITTRelationship Between System Organ Class and Verbatim Text 
(52-Week Treatment Pha se)IDSL
3.21. ITTAdverse Events of Special Interest by Category (52 -Week 
Treatment Phase)Benlysta StandardH
3.22. ITTAdverse Events of Special Interest by Category and 
Infusion for Treatment Holiday Group Re -Start PhaseBenlysta Standard
Laboratory Paramet ers
3.23. ITTLaboratory Results by Visit: Hematology (52 -Week 
Treatment Phase
3.24. ITTLaboratory Results by Visit: Liver Function (52 -Week Treatment 
Phase)
3.25. ITTLaboratory Results by Visit: Electrolytes (52- Week 
Treatment Phase)
3.26. ITTLaboratory Results by Visit: Other Chemistries (52 -Week 
Treatment Phase)
3.27. ITTLaboratory Results by Visit: Urinalysis (52- Week Treatment 
Phase)
3.28. ITTLaboratory Results by Visit: Immunoglobulins (52 -Week 
Treatment Phase)
3.29. ITTWorst Laboratory Toxicity Grade: Hematolo gy (52 -Week 
Treatment Phase)ICH E3 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
107Safety : Tables
No. Population Title Programming NotesPriority
Headline Results
Denoted by H
3.30. ITTWorst Laboratory Toxicity Grade: Liver Function (52 -Week 
Treatment Phase)ICH E3
3.31. ITTWorst Laboratory Toxicity Grade: Electrolytes (52 -Week 
Treatment Phase)ICH E3
3.32. ITTWorst Laboratory Toxicity Grade: Other Chemistries (52 -Week 
Treatment Phase)ICH E3
3.33. ITTWorst Laboratory Toxicity Grade: Urinalysis (52 -Week 
Treatment Phase)ICH E3
3.34. ITTWorst Laboratory Toxicity Grade: Immunoglobulins (52 -Week 
Treatment Phase)ICH E3
3.35. ITTLaboratory Toxicity Grade Worse ning of at Least 2 Grades from 
Baseline: Hematology (52-Week Treatment Phase)Benlysta Standard
3.36. ITTLaboratory Toxicity Grade Worsening of at Least 2 Grades from 
Baseline: Liver Function (52-Week Treatment Phase)Benlysta Standard
3.37. ITTLaboratory Toxi city Grade Worsening of at Least 2 Grades from 
Baseline: Electrolytes (52-Week Treatment Phase)Benlysta Standard
3.38. ITTLaboratory Toxicity Grade Worsening of at Least 2 Grades from 
Baseline: Other Chemistries (52-Week Treatment Phase)Benlysta Standard
3.39. ITTLaboratory Toxicity Grade Worsening of at Least 2 Grades from 
Baseline: Urinalysis (52-Week Treatment Phase)Benlysta Standard
3.40. ITTLaboratory Toxicity Grade Worsening of at Least 2 Grades from 
Baseline: Immunoglobulins (52 -Week Treatment Phase)Benlysta Standard
3.41. ITTLaboratory Reference Range Shifts from Baseline by Visit: 
Hematology (52 -Week Treatment Phase)Benlysta Standard 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
108Safety : Tables
No. Population Title Programming NotesPriority
Headline Results
Denoted by H
3.42. ITTLaboratory Reference Range Shifts from Baseline by Visit: Liver 
Function (52 -Week Treatment Phase)Benlysta Stan dard
3.43. ITTLaboratory Reference Range Shifts from Baseline by Visit: 
Electrolytes (52 -Week Treatment Phase)Benlysta Standard
3.44. ITTLaboratory Reference Range Shifts from Baseline by Visit: Other 
Chemistries (52 -Week Treatment Phase)Benlysta Standard
3.45. ITTLaboratory Reference Range Shifts from Baseline by Visit: 
Urinalysis (52 -Week Treatment Phase)Benlysta Standard
3.46. ITTLaboratory Reference Range Shifts from Baseline by Visit: 
Immunoglobulins (52 -Week Treatment Phase)Benlysta Standard
Immunoglobu lins
3.47. ITTImmunoglobulin Levels below the Lower Limit of Normal (LLN) 
by Visit (52 -Week Treatment Phase)Benlysta Standard
3.48. ITTImmunoglobulins below the Lower Limit of Normal (LLN) at each 
Visit among Subjects with Immunoglobulins >= LLN at Baseline 
(52-Week Treatment Phase)Benlysta Standard
3.49. ITTImmunoglobulins above the Lower Limit of Normal (LLN) at each 
Visit (52 -Week Treatment Phase)Benlysta Standard
3.50. ITTImmunoglobulins above the Lower Limit of Normal (LLN) at 
each Visit among Subjects with Immunoglobulins <= LLN 
at Baseline (52 -Week Treatment Phase)Benlysta Standard
Immunogenicity
3.51. ITT Immunogenic Response by Visit (52 -Week Treatment Phase) Benlysta Standard 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
109Safety : Tables
No. Population Title Programming NotesPriority
Headline Results
Denoted by H
Vital Signs
3.52. ITTVital Signs Change from Baseline by Visit (Observed) (52 -Week 
Treatment Phase)ICH E3 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
11013.11.8. Safety  Figures
Safety : Figures
No. Population Title Programming Notes Priority
Laboratory
3.1. ITTLaboratory Results by Visit: Hematology (52 -Week 
Treatment Phase)
3.2. ITTLaboratory Results by Visit: Liver Function (52 -Week Treatment 
Phase)
3.3. ITTLaboratory Results by Visit: Electrolytes (52 -Week Treatment 
Phase)
3.4. ITTLaboratory Results by Visit: Other Chemistries (52 -Week 
Treatment Phase)
3.5. ITTLaboratory Results by Visit: Other Chemistries (52 -Week 
Treatment Phase)
3.6. ITTLaboratory Results by Visit: Immunoglobulins (52 -Week 
Treatment Phase) 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
11113.11.9. Pharmacokinetic Tables
Pharmacokinetic : Tables
No. Population Title Programming Notes Priority
Belimumab Concentrations
4.1. PKBelimumab Concentrations (ug/ml) 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
11213.11.10. Pharmac okinetic Figures
Pharmacokinetic : Figures
No. Population Title Programming Notes Priority
Belimumab Concentrations
4.1. PKMedian Belimumab Concentrations (ug/mL): 52 -Week 
Treatment Phase
4.2. PKGeometic Mean Belimumab Concentrations (ug/mL): 52 -Week 
Treatment Phase
13.11.11. Biomarker Tables
Biomarker Tables
No. Population Title Programming Notes Priority
Autoantibodies
5.1. ITTAutoantibody Levels Change from Baseline by Visit 
(Observed) (52 -Week Treatment Phase)
5.2. ITTAutoantibody Levels Percent Change from Baseline by 
Visit (Observed) (52 -Week Treatment Phase)
5.3. ITTAutoantibody Levels Change from Baseline by Visit among 
Subjects Positive at Baseline (Observed) (52 -Week Treatment 
Phase) 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
113Biomarker Tables
No. Population Title Programming Notes Priority
5.4. ITTAutoantibody Levels Percent Change from Baseline by Visit 
among Subjects Positive at Baseline (Observed) (52- Week 
Treatment Phase)
5.5. ITTAutoantibody Levels Shift from Baseline by Visit 
(Observed) (52 -Week Treatment Phase)
Complement
5.6. ITTComplement Levels Change from Baseline by Visit (Observed) 
(52-Week Tre atment Phase)
5.7. ITTComplement Levels Percent Change from Baseline by Visit 
(Observed) (52 -Week Treatment Phase)
5.8. ITTComplement Levels Change from Baseline by Visit among 
Subjects Low at Baseline (Observed) (52- Week Treatment 
Phase)
5.9. ITTComplemen t Levels Percent Change from Baseline by Visit 
among Subjects Low at Baseline (Observed) (52 -Week 
Treatment Phase)
5.10. ITTComplement Levels Shift from Baseline by Visit (Observed) (52 -
Week Treatment Phase) 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
114Biomarker Tables
No. Population Title Programming Notes Priority
Immunoglobulins
5.11. ITTImmunoglobulins Change f rom Baseline by Visit (Observed) (52 -
Week Treatment Phase)
5.12. ITTImmunoglobulins Percent Change from Baseline by Visit 
(Observed) (52 -Week Treatment Phase)
5.13. ITTImmunoglobulins Change from Baseline by Visit among 
Subjects Low at Baseline (Observed) (5 2-Week Treatment 
Phase)
5.14. ITTImmunoglobulins Percent Change from Baseline by Visit 
among Subjects Low at Baseline (Observed) (52 -Week 
Treatment Phase)
5.15. ITTImmunoglobulin Levels Shift from Baseline by Visit (Observed) 
(52-Week Treatment Phase)
B-cells
5.16. ITTB-cells Change from Baseline by Visit (Observed) (52 -Week 
Treatment Phase)
5.17. ITTB-cells Percent Change from Baseline by Visit (Observed) (52 -
Week Treatment Phase)
5.18. ITTB-cells Change from Baseline by Visit (Observed) (52 -Week 
Treatment Pha se)
5.19. ITTB-cells Percent Change from Baseline by Visit (Observed) (52 -
Week Treatment Phase)
5.20. ITTB-cells Change from Week 24 by Visit (Observed) (Maintenance 
Phase) 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
115Biomarker Tables
No. Population Title Programming Notes Priority
5.21. ITTB-cells Percent Change from Week 24 by Visit (Observed) 
(Maintenance Phase)
BLyS Protein
5.22. ITTBLyS ProteinChange from Baseline by Visit (Observed) (52-
Week Treatment Phase)
5.23. ITTBLyS Protein Percent Change from Baseline by Visit (Observed) 
(52-Week Treatment Phase)
13.11.12. Biomarker Figures
Biomarker Figures
No. Population Title Programming Notes Priority
Autoantibodies
5.1. ITTAutoantibody Levels Percent Change from Baseline by 
Visit (52 -Week Treatment Phase)
5.2. ITTAutoantibody Levels Percent Change from Baseline by 
Visit among Subjects Positive at Baseline (52 -Week 
Treatment Phase)
Complement
5.3. ITTComplement Levels Percent Change from Baseline by 
Visit (52 -Week Treatment Phase)
5.4. ITTComplement Levels Percent Change from Baseline by 
Visit among Subjects Positive at Baseline (52 -Week 
Treatment Phase) 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
116Biomarker Figures
No. Population Title Programming Notes Priority
Immunoglobulins
5.5. ITTImmunoglobulin Levels Percent Change from Baseline by 
Visit (52 -Week Treatment Phase)
5.6. ITTImmunoglobulin Levels Percent Change from Baseline by 
Visit among Subjects Positive at Baseline (52 -Week 
Treatment Phase)
BLyS Protein
5.7. ITTBLyS Protein Percent Change from Baseline by Visit (52 -Week 
Treatment Phase)
B cell Subsets
5.8. ITTB Cell Percent Change from Baseline by Visit (52 -Week 
Treatment Phase)
5.9.B Cell Percent Change from Week 24 by Visit (52 -Week 
Treatment Phase)
5.10. ITTB Cell Absolut e Values by Visit and Subject for Subjects 
who Enter the Maintenance Phase 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
11713.11.13. ICH Listings
ICH: Listings
No. Population Title Programming Notes Priority
Subject Disposition
1. Screened Reasons for Screen Failure   Journal requirements
2. Screened Re-Screened Subjects
3. ITT Subject Disposition and Population Status ICH E3
4. ITT Previous Trial History ICH E3
5. ITT Reasons for Study Withdrawal ICH E3
Protocol Deviations
6. Screened Subjects with Inclusion/Exclusion Criteria Deviations ICH E3
7. Scree ned Important Protocol Deviations ICH E3
Demographic and Baseline Characteristics
8. ITT Demographic and Baseline Characteristics ICH E3
9. ITT General Medical History ICH E3
10. ITT Subjects Who Took Prohibited Medications Study specific
Prior and Conco mitant Medications
11. ITT Concomitant Medications ICH E3
Exposure and Treatment Compliance
12. ITT Study Agent Administration ICH E3
Adverse Events
13. ITT All Adverse Events ICH E3 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
118ICH: Listings
No. Population Title Programming Notes Priority
14. ITT Subject Numbers for Individual Adverse Events ICH E3
15. ITTRelation ship Between Adverse Event System Organ Classes, 
Preferred Terms, and Verbatim TextIDSL
Serious and Other Significant Adverse Events
16. ITT Serious Adverse EventsStudy specific/ ICH E3 (other 
significant events)
17. ITT Deaths ICH E3
18. ITT Non-Fatal Ser ious Adverse Events ICH E3
19. ITT Study Treatment Related Adverse EventsStudy specific/ ICH E3 (other 
significant events)
20. ITT Adverse Events Resulting in Study Treatment Discontinuation ICH E3
21. ITT Pre-treatment Adverse EventsStudy specific/ ICH E3 (other 
significant events)
22. ITT Adverse Events of Special InterestStudy specific/ ICH E3 (other 
significant events)
23. ITT Malignancy Adverse Events of Special InterestStudy specific/ ICH E3 (other 
significant events)
24. ITT Reasons for Considering as a Serious Adverse Event ICH E3
25. ITT Infusion Related Systemic Reactions Study specific
26. ITT Concomitant Procedures/Surgery Study specific
Vital Signs
27. ITT Vital Signs IDSL
All Laboratory
28. ITT Laboratory Results: Hematology 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
119ICH: Listings
No. Population Title Programming Notes Priority
29. ITT Laboratory Res ults: Liver Function
30. ITT Laboratory Results: Electrolytes
31. ITT Laboratory Results: Other Chemistries
32. ITT Laboratory Results: Urinalysis
33. ITT Laboratory Results: Immunoglobulins
34. ITTGrade 3 or Grade 4 Laboratory Toxicity Results: 
Hematolog y
35.ITT Grade 3 or Grade 4 Laboratory Toxicity Results: Liver 
Function
36.ITT Grade 3 or Grade 4 Laboratory Toxicity Results: 
Electrolytes
37.ITT Grade 3 or Grade 4 Laboratory Toxicity Results: Other 
Chemistries
38.ITT Grade 3 or Grade 4 Laboratory To xicity Results: 
Urinalysis
39. ITTGrade 3 or Grade 4 Laboratory Toxicity Results: 
Immunoglobulins
Hepatobiliary (Liver)
40. ITT Liver Monitoring Stopping Event Reporting
41. ITT Medical Conditions for Participants with Liver Stopping Events
42. ITT Substance Use for Participants with Liver Stopping Events 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
12013.11.14. Non- ICH Listings
Non-ICH: Listings
No. Population Title Programming Notes Priority
Efficacy Endpoints
43. ITT SFI Flares Study specific
44. ITT SELENA -SLEDAI Analysis Results Study specific
45. ITT Physician’s Global Assessment (PGA) Analysis Results Study specific
46. ITT Average Daily Prednisone Dose Study specific
Immunogenicity
47. ITT Immunogenicity Results Study specific
SLICC
48. ITT SLICC/ACR Damage Index Analysis Results Study specific
Belimumab PK Concentration
49. PK Serum Belimumab PK Concentration -Time Data Study specific
Biomarkers
50. ITT Autoantibody and Complement Results Study specific
51. ITT B Cell Results Study specific 
 
 2018N381035_00
CONFIDENTIA L
BEL116027
12113.12. Appendix 12: Example Mock Shells for Data Display s
Data Displ ay Specification will be made available on Request 
 
 2018N381035_00